TITLE: Extensive cryptic circulation sustains mpox among men who have sex with men

AUTHORS: Joseph A. Lewnard[1,2,*], Miguel I. Paredes[3], Matan Yechezkel[1], Gregg S. Davis[4], Vennis Hong[4], Jessica Skela[4], Utsav Pandey[5,6], Noah T. Parker[1,7], Lauren C. Granskog[1], Magdalena E. Pomichowski[4], Iris Anne C. Reyes[4], Isabel Rodriguez Barraquer[8,9], Nicola F. Müller[8], Sara Y. Tartof[4,10,*]

AFFILIATIONS:

1. Division of Epidemiology, School of Public Health, University of California, Berkeley; Berkeley, California 94720, United States
2. Center for Computational Biology, College of Computing, Data Science, and Society, University of California, Berkeley; Berkeley, California 94720, United States
3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, Washington 98109, United States
4. Department of Research & Evaluation, Kaiser Permanente Southern California; Pasadena, California 91101, United States
5. Regional Reference Laboratories, Kaiser Permanente Southern California; Chino Hills, California 91709, United States
6. Department of Clinical Science, Bernard J. Tyson School of Medicine; Pasadena, California 91101, United States
7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, United States
8. Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco; San Francisco, California 94518, United States
9. Chan Zuckerberg Biohub, San Francisco, California 94518, United States
10. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine; Pasadena, California 91101, United States

† Equal contributors

* Addresses for correspondence:

Joseph A. Lewnard
2121 Berkeley Way
Berkeley, California 94720
United States
jLewnard@berkeley.edu
+1-510-664-4050

Sara Y. Tartof
100 S. Los Robles
Pasadena, California 91101
United States
Sara.Y.Tartof@kp.org
+1-626-564-3001

ABSTRACT: Sporadic cases of mpox continue among men who have sex with men (MSM), with most lacking identifiable transmission links. To resolve underlying dynamics, we prospectively tested for monkeypox virus (MPXV) in rectal swabs from MSM in Los Angeles during summer, 2024, finding that infections exceeded reported mpox cases 33-fold (95% confidence interval: 16-68). Accounting for under-reporting, incidence rates of MPXV infection were comparable to *Neisseria gonorrhoeae* and *Chlamydia trachomatis* among MSM. Independent estimates derived from MPXV phylogenetic reconstruction and a meta-analysis of surveillance studies corroborated this extensive under-reporting. We estimate that undiagnosed infections must cause at least 31-44% of all transmission to explain observed MPXV phylogenies; under realistic modeling assumptions, this proportion rises to 61-94%. Contrary to current guidance, our findings suggest MPXV is prevalent among MSM, predominantly causes subclinical infection, and is sustained in circulation by cryptic transmission.

MAIN TEXT: Since 2022, clade IIb monkeypox virus (MPXV) has continued to spread sexually among men who have sex with men (MSM) and other sexual- and gender-minority populations in countries where it was previously non-endemic (*1*). Clinically, mpox is associated with a prodrome characterized by fever, chills, myalgia, and lymphadenopathy, followed by painful cutaneous or mucosal lesions, often localized to sites of sexual exposure (*2*). Current US Centers for Disease Control & Prevention (CDC) guidance stipulates that symptomatic individuals drive transmission “from the time symptoms start until the rash has fully healed and a fresh layer of skin has formed” (*3*), and advises against asymptomatic testing in high-risk populations on the premise that undetected infections are uncommon (*4–6*). Declines in reported case counts to sporadic daily detections have accordingly been interpreted as evidence of successful outbreak containment (*7*).

However, experience during the ongoing epidemic has suggested cryptic transmission falling outside this paradigm. Across numerous settings, >90% of mpox cases have lacked epidemiological links to prior cases, and 67-85% have reported no known exposure to individuals with mpox or mpox-like symptoms (*2, 8–11*). Individuals shed replication-competent MPXV before symptoms onset and during subclinical infection *(12–14*), and pre-symptomatic transmission is widely documented (*2, 15–17*), implying that contact with lesions is not required for MPXV spread. Although quantifying the proportion of individuals that become symptomatic and receive diagnoses could clarify the epidemiological importance of subclinical MPXV infections, ascertainment ratios for clade IIb MPXV remain unknown.

To resolve this uncertainty, we launched a prospective surveillance study among Los Angeles MSM receiving healthcare from Kaiser Permanente Southern California (KPSC). The KPSC healthcare system provides comprehensive, integrated care to members; electronic health records (EHRs) record all diagnoses, clinical notes, laboratory tests, procedures, immunizations, and pharmacy prescriptions. Insurance reimbursement data capture out-of-network care, and history of vaccination with JYNNEOS (modified *Vaccinia* Ankara) is automatically reconciled with the California Immunization Registry, to which providers statewide are required to report all vaccine administrations. Our study cohort comprised 7,930 males aged 16-52 years on May 1, 2024, with ≥1 year of prior enrollment and ≥1 anorectal test for *Chlamydia trachomatis* or *Neisseria gonorrhoeae* infection—an indication reserved for MSM. From May 29 to November 13, 2024, we tested eligible cohort members' remnant anorectal specimens collected for *C. trachomatis*/*N. gonorrhoeae* screening—which sexually-active MSM are recommended to receive as often as every 3-6 months—for MPXV DNA via real-time polymerase chain reaction (PCR), while concurrently monitoring for mpox diagnoses in any clinical care setting.

Subclinical MPXV infections vastly outnumber diagnosed cases. The incidence rate of laboratory-confirmed mpox diagnoses identified through standard-of-care testing in clinical settings was 0.61 (95% confidence interval: 0.27-0.77) cases per 100 person-years at risk among cohort members (*n*=15 cases) in analyses weighted to balance demographic and clinical characteristics of individuals who received or did not receive screening tests (**Fig. S1**; **Table S1**). Accounting solely for virus shedding among diagnosed cases, we expected a weighted MPXV prevalence of 0.035% in anorectal swabs (**Fig. 1A**; **Table S2**; **Fig. S2**). In contrast, testing 1,190 remnant anorectal specimens from 1,054 individuals, we identified 7 positive results among 6 individuals, yielding a markedly higher weighted estimates of MPXV prevalence (0.91% [0.40-1.6%] and incidence (20 [8.5-48] infections per 100 person-years).

No individuals testing positive for MPXV via anorectal specimen surveillance sought clinical care relating to mpox symptoms or received diagnostic testing during the study period, suggesting the infections we identified through rectal testing were asymptomatic or paucisymptomatic. In total, the 6 individuals testing positive for MPXV received 11 *N. gonorrhoeae*/*C. trachomatis* screening tests over the study period. One was receiving treatment for HIV infection, while 4 were receiving tenofovir-emtricitabine for HIV pre-exposure prophylaxis. The remaining individual not receiving antiviral treatment for HIV care or prevention was tested twice during the study period for sexually-transmitted infections (STIs), and received antibiotic treatment for both *N. gonorrhoeae* and *C. trachomatis* concurrently with his positive MPXV swab.

We used a likelihood-based framework to estimate an under-reporting multiplier relating daily anorectal MPXV test positivity to expected rates of infection acquisition, shedding, and clearance derived from diagnosed cases. By this approach, we estimated that only 1 in 33 (16-68) MPXV infections received a laboratory-confirmed mpox diagnosis (**Fig. 1C**). Under-reporting multiplier estimates varied by healthcare engagement and demographic characteristics; predictors of higher under-reporting included younger age, lack of HIV pre-exposure prophylaxis or doxycycline post-exposure prophylaxis, no prior-year STI testing or diagnoses, having <5 healthcare visits in the prior year, and receipt of health insurance through non-commercial sources (**Fig. 1D**). Sensitivity analyses excluding repeat positive results or closely spaced consecutive swabs (<30 days) yielded similar results, while an alternative, cross-sectional analysis comparing time-matched observed and expected MPXV prevalence estimated that 1 in 26 (12-47) infections was diagnosed (**Table S3**).

Contrary to the low apparent incidence of mpox diagnoses, incidence of MPXV infection within the KPSC study cohort occurred at rates comparable to bacterial STIs for which MSM are recommended to receive routine testing. Estimated incidence rates of *N. gonorrhoeae* and *C. trachomatis* infection totaled 25 (21-30) and 12 (9.5-16) acquisitions per 100 person-years, respectively, over the same period (**Fig. 1B**). Among persons without prior syphilis diagnoses, incidence of syphilis (*Treponema pallidum*) infections was substantially lower than incidence of MPXV infection (7.0 [4.3-11.5] versus 21 [8.0-57] acquisitions per 100 person-years), further highlighting the unexpected scale of MPXV transmission.

Vaccination provides non-sterilizing protection against MPXV infection. Among the study cohort, pre-exposure vaccination with JYNNEOS demonstrated 72% (9.4-91%) effectiveness against diagnosed mpox (78% for two doses, 55% for one dose; **Fig. 2A**; **Table S4**), consistent with prior estimates (*18*). However, two different analysis frameworks suggested this effect was only partially mediated by protection against MPXV infection acquisition, with previously vaccinated individuals accounting for 5 of the 6 subclinical infections identified through anorectal specimen testing. Weighted incidence rates of MPXV infection were 51% (–92-95%) lower among JYNNEOS recipients than non-recipients

(**Fig. 2B**), and vaccination was associated with 53% (–167-92%) effectiveness against anorectal MPXV infection within our surveillance study (59% for two doses, 41% for one dose; two-sided p>0.1). JYNNEOS recipients who acquired MPXV infection experienced 41% (–245-90%) lower risk of diagnosed mpox than unvaccinated individuals who acquired infection. Although imprecise due to low counts of subclinical infections, these estimates corroborate prior evidence that vaccination with JYNNEOS reduces mpox severity rather than conferring sterilizing immunity against MPXV infection (*19–21*).

Nearly all vaccinated individuals within the study population received JYNNEOS during acute phases of the mpox outbreak between July and October, 2022 (**Fig. 2C**), when vaccine delivery occurred not only in primary care settings but at mass vaccination sites, STI clinics, commercial sex venues, and mobile clinics at MSM-frequented events (*22*). Low coverage among individuals aged <18 in 2022 (12%) in comparison to individuals aged ≥18 years at that time (60%; **Fig. 2D**) underscores the ongoing growth of an undervaccinated MSM cohort that faces prevalent exposure to MPXV.

Subclinical infections drive ongoing MPXV circulation. Under a scenario in which undetected MPXV infections do not meaningfully contribute to onward spread (*3–6*), diagnosed mpox cases (representing 3.0% of total infections) would necessarily account for all MPXV transmission. Such extreme concentration of transmission implies superspreading dynamics characterized by a very low dispersion parameter (k), which quantifies heterogeneity in infectiousness in epidemiological models (*23–25*). However, contrary to this scenario, previous phylogenetic analyses have estimated k values between 0.30-0.32 for MPXV transmission during the current clade IIb outbreak (*26–28*), similar to estimates for *N. gonorrhoeae* among MSM (k=0.26; (*29*)). Models excluding transmission by undetected infections—and minimizing dispersion by assuming uniform numbers of secondary infections among all diagnosed mpox cases—yielded maximal k estimates well below these previous estimates, ranging from 0.047 (0.021-0.092) to 0.082 (0.036-0.16) for scenarios with a reproduction number (R) between 0.7-3.5 (**Fig. 3A**). Sensitivity analyses allowing transmission by 6.0% of the population—consistent with a lower under-reporting multiplier or 50% ascertainment fraction for individuals with clinical illness—likewise provided weak statistical support for this scenario (2.3-11% probability for k≥0.3 with R<1, and <1% probability with R≥1).

We therefore quantified the contribution of undetected infections to transmission under more realistic scenarios with MPXV dispersion characteristics mirroring prior observations (k=0.3). Maximizing the proportion of transmission attributable to diagnosed cases via a deterministic framework, we estimated that individuals with undetected infection must account for a minimum of 31% (29-34%) to 44% (40-47%) of all transmission events (**Fig. 3B**). This estimated attributable fraction exceeded half of all transmission under less-restrictive modeling assumptions allowing differences in infectiousness among individuals with diagnosed or undiagnosed infections (**Fig. 3C**). Assuming individuals with diagnosed infection are 20-fold more likely to transmit MPXV compared to undetected cases, the proportion of transmission attributable to undetected infections was 61% (43–78%). Assuming weaker differences in infectiousness (only a 2-fold increase for diagnosed cases relative to undetected infections), the contribution of undetected infections rose to 94% (88–97%). Thus, to explain dispersion patterns evident in MPXV phylogenies, undetected infections must play a meaningful role in sustaining viral transmission.

Under-reporting is geographically widespread and confirmed by phylogenetic analyses. To understand the external generalizability of our results, we next compared evidence of under-reporting within the KPSC cohort to data from other settings. Numerous surveillance studies have identified undetected MPXV infections based on anorectal shedding or serological evidence of prior infection, although implications of these findings for local mpox reporting fractions remain unknown. We undertook a systematic review of epidemiological studies conducting molecular or antibody-based testing for MPXV infection among MSM, and compared findings from 10 studies meeting eligibility criteria (*5, 6, 12, 14, 30–35*) to mpox case notifications from the same settings (**Tables S5**–**S7**; **Fig. S3**). In studies testing for MPXV shedding via anorectal specimens (*6, 12, 14, 30–32*), observed prevalence exceeded expected prevalence based on reported cases by factors of 51-525 (**Figure 4A**). Adjusting for potential higher-risk behavior in tested populations (**Fig. S4**), under-reporting factor estimates ranged from 36-377. Serological studies yielded lower but still substantial under-reporting factors (7.0-69 unadjusted, 5.0-50 adjusted; **Fig. 4B** (*5, 6, 33–35*)). In the single study employing both molecular and serological testing (*6*), under-reporting estimates based on molecular testing exceeded those based on serological testing by a factor of 4.0 (0.86-15), suggesting differences across these classes of studies were driven by lower sensitivity of serological testing.

To further validate these findings using a distinct analytical framework and data source, we next estimated under-reporting multipliers via phylogenetic reconstruction of MPXV transmission within Los Angeles County. Leveraging data from 497 clade IIb MPXV genomes sampled locally alongside 7,140 publicly available global sequences collected between May 2022 and December 2024, we fit a birth-death skyline model (*36*) to local outbreak clusters using Markov chain Monte Carlo in BEAST2, as described previously (*26, 27, 37*), and used estimates of the sampling proportion to compute under-reporting multipliers (*38*). Validating this framework for estimating the sampling proportion (**Fig. S5**), we estimated that MPXV infections outnumbered reported cases by a factor of 28 (19-43) from October 15, 2022 to December 31, 2024, and by a factor of 13 (7.4-24) during the preceding emergency phase of the outbreak (**Fig. 4C**-**D**; **Fig. S6**). This 49% (23-96%) reduction in the proportion of MPXV infections receiving diagnoses after October 15, 2022 aligns with the rapid

rollout of JYNNEOS for at-risk MSM: 76% of Los Angeles County recipients of JYNNEOS (*39*), and 49% of all members of the KPSC study cohort, were vaccinated by October 15, 2022.

Discussion. Our results demonstrate frequent undetected clade IIb MPXV infections among MSM, with infections outnumbering diagnosed cases by 26- to 33-fold margins within a cohort of Los Angeles MSM during summer, 2024. Independent molecular surveillance, serological studies, and phylogenetic analyses support this finding of extensive under-reporting. Within the study cohort, we observed modest (51-53%) vaccine-derived protection against MPXV infection, while replicating prior estimates of vaccine effectiveness against diagnosed mpox (*18*). Our observations align with previous evidence that vaccination reduces disease severity (*19–21*) rather than providing sterilizing immunity against MPXV, and suggest mild infections among MSM who previously received JYNNEOS individuals feature prominently in mpox epidemiology following large-scale vaccination campaigns in 2022 (*40*). The low estimated reporting fraction further implies that undetected infections contribute substantially to transmission, contradicting current guidance that suggests undetected infections are uncommon (*4*) and emphasizes symptom-driven transmission (*3*).

To our knowledge, no prior studies have estimated the proportion of MPXV infections that are clinically diagnosed. One study used case exposure history to estimate reporting fractions, but analyses concerned only the population experiencing disease warranting diagnostic testing (*41, 42*), who do not fully represent the clinical spectrum of MPXV infections. A study prospectively monitoring contacts of mpox cases for MPXV infection reported symptoms among 46% of individuals who tested positive (*13*), although intensive monitoring likely enhanced case ascertainment among individuals with mild clinical presentations in this study. Across multiple molecular screening studies included in our meta-analysis, 22% (11/49) of MPXV-positive participants who were followed up reported symptoms or received clinical diagnoses (**Table S8**; (*6, 12, 14, 30–32*)), while a seroprevalence study from 2022 reported that only 13% of individuals with evidence of prior infection recalled recent rash or lesions (*33*). In a 2022 study of US MSM, 18% and 7% of participants who experienced rash with and without fever during the outbreak peak (June-August), respectively, were tested for mpox (*43*), suggesting case ascertainment may be suboptimal even among individuals who experience symptoms.

Our findings augment a growing body of observations compatible with MPXV transmission by individuals with inapparent infection. Consistent with our finding that undetected infections account for at least 31-44%, and likely 61-94%, of transmission, 67-85% of mpox cases in previous studies have reported no known exposure to individuals with mpox or mpox-like symptoms (*2, 8–11*). Furthermore, 28-77% of transmission events in studies of linked mpox cases involved pre-symptomatic exposures, confirming that contact with lesions is not requisite for spread (*2, 15, 17*). Shedding of replication-competent MPXV occurs before symptoms onset and during asymptomatic infection in oral, anal, and genital mucosa, providing a plausible a mechanism of transmission besides skin-to-lesion contact (*12–14*). Last, infection risk is strongly associated with condomless anal or vaginal sex (*2, 35, 44*), which may be incompatible with the severe pain cases report while experiencing lesions (*45*).

Monitoring MPXV shedding and incident disease in a single cohort, with detailed demographic and healthcare utilization data, enabled direct comparison of MPXV shedding prevalence to mpox diagnoses. Under-reporting multipliers based on estimates from molecular and serological surveillance studies, as well as phylogenetic analyses, validated our conclusions. However, our study has limitations. Although anorectal swabs are optimal for identifying subclinical MPXV infections (*13, 46*), studies using multiple specimen sources have identified further infections based on oropharyngeal swabs alone (*14, 44*). Our estimates may thus represent a lower-bound for the extent of under-reporting of MPXV infections within the KSPC study cohort. With 6 infections identified by anorectal specimen testing, assessments of vaccine effectiveness against infection were underpowered; nonetheless, consistency of our point estimates under two analysis frameworks supports their validity. Our analyses of prior molecular and serosurveillance studies lacked individual-level metadata, and relied on uncertain estimates of MSM population denominators for each setting, likely contributing to wide variation in estimates. Differences in under-reporting multiplier estimates based on molecular and serological testing may indicate greater sensitivity of PCR testing. Alternatively, as most studies were undertaken near the peak of the outbreak in 2022, delayed seroresponse among recently-infected individuals could contribute to underestimation of infections (*47*). Last, differential sequencing efforts globally, and non-random sequencing of transmission clusters in Los Angeles County, could impact our ability to infer MPXV introductions and estimate transmission-dynamic parameters within our phylogenetic analyses.

Collectively, our results challenge prevailing assumptions underlying symptom-based mpox surveillance and support reconsideration of control strategies in light of widespread and clinically inapparent MPXV circulation. Current surveillance efforts relying on lesion-based clinical testing do not accurately convey individuals' likelihood of exposure to MPXV among sexual contacts, and declining case notifications should not be interpreted as evidence of successful containment (*7*). Public health strategies reliant on symptom-based testing, isolation, and contact tracing are unlikely to be effective in curtailing MPXV transmission. After relaxation of enhanced efforts to distribute JYNNEOS widely during emergency phases of the mpox response, young MSM, in particular, have low vaccine coverage and may be at risk of severe mpox amid ongoing exposure to MPXV circulation. Long-term control strategies ensuring continued access to JYNNEOS and reliable monitoring of infection prevalence are needed to manage MPXV as an endemic STI among MSM.

REFERENCES AND NOTES:

1. Minhaj FS, Ogale YP, Whitehill F, Schultz J, Foote M, Davidson W, et al. Monkeypox Outbreak — Nine States, May 2022. *Morb Mortal Wkly Rep* **71**, 764–9 (2022).

2. Snyder RE, Saadeh K, Tang EC, Johnson KA, Holland SN, Quint J, et al. Sexual exposures associated with mpox infection: California, November, 2022 to June, 2023. *J Infect Dis* **229**, S188–96 (2024).

3. US Centers for Disease Control & Prevention. How mpox spreads (2025); https://www.cdc.gov/mpox/causes/index.html.

4. US Centers for Disease Control & Prevention. Getting tested for mpox (2025); https://www.cdc.gov/mpox/testing/index.html.

5. Minhaj FS, Singh V, Cohen SE, Townsend MB, Scott H, Szumowski J, et al. Prevalence of undiagnosed monkeypox virus infections during global mpox outbreak, United States, June–September, 2022. *Emerg Infect Dis* **29**, 2307–14 (2023).

6. Ogale YP, Baird N, Townsend MB, Berry I, Griffin I, Lee M, et al. Evidence of mpox virus infection among persons without characteristic lesions or rash presenting for first dose of JYNNEOS vaccine—District of Columbia, August 2022. *Clin Infect Dis* **77**, 298–302 (2023).

7. Daskalakis D, Romanik N, Jha AK. Lessons from the mpox response. JAMA **331**, 387–8 (2024).

8. Gobierno de España, Instituto de Salud Carlos III. Monkeypox: surveillance results (2025); https://cne.isciii.es/en/servicios/enfermedades-transmisibles/enfermedades-a-z/viruela-monos-monkeypox/resultados-vigilancia.

9. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 countries — April–June, 2022. *NEJM* **387**, 679–91 (2022).

10. UK Health Security Agency. Investigation into monkeyox outbreak in England: technical briefing 3 (2024). https://www.gov.uk/government/publications/monkeypox-outbreak-technical-briefings/investigation-into-monkeypox-outbreak-in-england-technical-briefing-3. ‘’

11. van Ewijk CE, Miura F, van Rijckevorsel G, de Vries HJ, Welkers MR, van den Berg OE, et al. Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine. *Eurosurveillance* **28**, 2200772 (2024).

12. De Baetselier I, Van Dijck C, Kenyon C, Coppens J, Michiels J, de Block T, et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. *Nat Med* **28**, 2288–92 (2022).

13. Brosius I, Dijck CV, Coppens J, Vandenhove L, Bangwen E, Vanroye F, et al. Presymptomatic viral shedding in high-risk mpox contacts: a prospective cohort study. *J Med Virol* **95**, e28769 (2023).

14. Agustí C, Martínez-Riveros H, Hernández-Rodríguez À, Casañ C, Díaz Y, Alonso L, et al. Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain. *Nat Commun* **14**, 5998 (2023).

15. Ward T, Christie R, Paton RS, Cumming F, Overton CE. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study. *BMJ* **379**, e073153 (2022).

16. Kubo T, Hayakawa K, Akiyama Y, Morioka S, Ohmagari N. A case of confirmed pre-symptomatic transmission of mpox. *J Infect Chemother* **29**, 1008–9 (2023).

17. Miura F, Backer JA, van Rijckevorsel G, Bavalia R, Raven S, Petrignani M, et al. Time scales of human mpox transmission in the Netherlands. *J Infect Dis* **229**, 800–4 (2024).

18. Pischel L, Martini BA, Yu N, Cacesse D, Tracy M, Kharbanda K, et al. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. *Vaccine* **42**, 126053 (2024).

19. Granskog L, Saadeh K, Lorenz K, Quint J, Salih T, Lo T, et al. Effect of JYNNEOS vaccination on mpox clinical progression: a case–control study. *Lancet Infect Dis*, doi:10.1016/S1473-3099(25)00180-X (2025)

20. Guagliardo SAJ. Monkeypox virus infections after 2 preexposure doses of JYNNEOS vaccine — United States, May, 2022–May, 2024. *Morb Mortal Wkly Rep* **73**, 460–6 (2024)

21. Farrar JL, Lewis NM, Houck K, Canning M, Fothergill A, Payne AB, et al. Demographic and clinical characteristics of mpox in persons who had previously received 1 dose of JYNNEOS vaccine and in unvaccinated persons — 29 US jurisdictions, May 22–September 3, 2022. *Morb Mortal Wkly Rep* **71**, 1610–5 (2022).

22. Kahn PA, Ying X, Virata M, Magahis P, Li S, Mathis WS. Availability and accessibility of live nonreplicating smallpox/mpox vaccine. *JAMA Netw Open* **6**, e237873 (2023).

23. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. *Nature* **438**, 355–9 (2005).

24. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science* **371**, eabe2424 (2021).

25. Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan BC, Neelima S, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* **370**, 691–7 (2020).

26. Paredes MI, Ahmed N, Figgins M, Colizza V, Lemey P, McCrone JT, et al. Underdetected dispersal and extensive local transmission drove the 2022 mpox epidemic. *Cell* **187**,1374-1386.e13 (2024).

27. Paredes MI, Liang C, Suen S chuan, Holloway IW, Garrigues JM, Green NM, et al. Viral introductions and return to baseline sexual behaviors maintain low-level mpox incidence in Los Angeles County, USA, 2023–2024. medRxiv. 2025 Mar 15;2025.03.14.25323999.

28. Maniscalco D, Robineau O, Boëlle PY, Mazzoli M, Barret AS, Chazelle E, et al. Adaptive behavior in response to the 2022 mpox epidemic in the Paris region. *medRxiv* [Preprint] (2024) doi:10.1101/2024.10.25.24315987v1.

29. Whittles LK, White PJ, Didelot X. A dynamic power-law sexual network model of gonorrhoea outbreaks. *PLoS Comput Biol* **15**, e1006748 (2019).

30. Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, et al. Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France. *Ann Intern Med* **175**, 1491–2 (2022).

31. Dijck CV, Baetselier ID, Kenyon C, Liesenborghs L, Dijck CV, Baetselier ID, et al. Mpox screening in high-risk populations finds no asymptomatic cases. Lancet Microbe, **4**, e132–3 (2023).

32. Hampel B, Farnham A, Lamothe-Molina PJ, Capelli C, Schibler M, Alonso PU, et al. Low prevalence of asymptomatic mpox in populations at high risk. *Lancet Microbe* **4**, e856 (2023).

33. Pathela P, Townsend MB, Kopping EJ, Tang J, Navarra T, Priyamvada L, et al. Serological evidence of mpox virus infection during peak mpox transmission in New York City, July to August, 2022. *J Infect Dis* **230**, jiae181 (2024).

34. Matusali G, Mazzotta V, Piselli P, Bettini A, Colavita F, Coen S, et al. Asymptomatic mpox virus infection in subjects presenting for MVA-BN vaccine. *Clin Infect Dis* **77**, 1483–4 (2023).

35. Marcus U, Michel J, Lunchenkov N, Beslic D, Treindl F, Surtees R, et al. A seroprevalence study indicates a high proportion of clinically undiagnosed MPXV infections in men who have sex with men in Berlin, Germany. *BMC Infect Dis* **24**, 1153 (2024).

36. Stadler T, Kühnert D, Bonhoeffer S, Drummond AJ. Birth–death skyline plot reveals temporal changes of epidemic spread in HIV and hepatitis C virus (HCV). *Proc Natl Acad Sci U S A* **110**, 228–33 (2013).

37. Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M, Gavryushkina A, et al. BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis. *PLoS Comput Biol* **15**, e1006650 (2019).

38. Li LM, Grassly NC, Fraser C. Quantifying transmission heterogeneity using both pathogen phylogenies and incidence time series. *Mol Biol Evol* **34**, 2982–95 (2017).

39. Los Angeles County Department of Public Health. Mpox in Los Angeles County (2025). https://app.powerbigov.us/view?r=eyJrIjoiNGI5MmEyMmQtYzVjMS00OTgwLWFhMDgtM2YyMTkxMjJlNmFhIiwidCI6IjA3NTk3MjQ4LWVhMzgtNDUxYi04YWJlLWE2MzhlZGRiYWM4MSJ9.

40. Kriss JL, Boersma PM, Martin E, Reed K, Adjemian J, Smith N, et al. Receipt of first and second doses of JYNNEOS vaccine for prevention of monkeypox — United States, May 22–October 10, 2022. *Morb Mortal Wkly Rep* **71** (2022).

41. Ward T, Overton CE, Paton RS, Christie R, Cumming F, Fyles M. Understanding the infection severity and epidemiological characteristics of mpox in the UK. *Nat Commun* **15**, 2199 (2024).

42. Tsang TK, Wang C, Yang B, Cauchemez S, Cowling BJ. Using secondary cases to characterize the severity of an emerging or re-emerging infection. *Nat Commun* **12**, 6372 (2021).

43. Atkins K, Carpino T, Rao A, Sanchez T, Edwards OW, Hannah M, et al. Suspected mpox symptoms and testing in men who have sex with men in the United States: cross-sectional study. *JMIR Public Health Surveill* **11**, e57399 (2025).

44. Koppe U, Jansen K, Schmidt AJ, Weber C, Schulze H, Kulis-Horn RK, et al. Clinically inapparent mpox virus (MPXV) infections among clients of three anonymous Community Based Voluntary Counselling and Testing centres in Berlin, Germany, 2022–2023. *BMC Infect Dis* **24**, 613 (2024).

45. Witzel TC, Ghobrial A, Palich R, Charles H, Rodger AJ, Sabin C, et al. Experiences of mpox illness and case management among cis and trans gay, bisexual and other men who have sex with men in England: a qualitative study. *eClinicalMedicine* **70**, 102522 (2024).

46. Kim H, Kwon R, Lee H, Lee SW, Rahmati M, Koyanagi A, et al. Viral load dynamics and shedding kinetics of mpox infection: a systematic review and meta-analysis. *J Travel Med* **30**, taad111 (2023).

47. Charniga K, Park SW, Akhmetzhanov AR, Cori A, Dushoff J, Funk S, et al. Best practices for estimating and reporting epidemiological delay distributions of infectious diseases. *PLoS Comput Biol* **20**: e1012520 (2024).

Acknowledgments: The authors are indebted to the staff of the Molecular Microbiology Department at the Southern California Permanente Medical Group, Regional Reference Laboratory, Chino Hills for their support and contributions to this study.

Funding: This work was funded by the Center for Forecasting and Outbreak Analytics of the US Centers for Disease Control & Prevention via the Insight Net cooperative agreement (CDC-RFA-FT-23-0069 to SYT and JAL). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

Author contributions: Conceptualization: JAL, MIP, NFM, SYT; Methodology: JAL, MIP, GSD, UP, NFM; Investigation: JAL, MIP, MY, GSD, VH, JS, UP, NTP, LCG, NFM, SYT; Visualization: JAL, MIP; Funding acquisition: JAL, IRB, SYT; Project administration: JAL, MEP, IACR, SYT; Supervision: JAL, NFM, SYT; Writing—original draft: JAL, MIP, NFM; Writing—review & editing: JAL, MIP, MY, GSD, VH, JS, UP, NTP, LCG, MEP, IACR, IRB, NFM, SYT.

Competing interests: The authors report no conflicts of interest relevant to this work.



Fig. #1. Prevalence and incidence of MPXV infection, and predictors of under-reporting. (**A**) We present estimates of expected prevalence of MPXV infection accounting only for shedding among cases receiving mpox diagnoses (purple line) alongside estimates of observed prevalence based on anorectal specimen testing (blue line, shaded area corresponding to 95% confidence intervals, presented as a moving 3-week average). Dotted lines convey prevalence estimates outside the period where a 3-week moving average could be computed for MPXV detection in anorectal specimens. We illustrate results on an absolute scale in the top-right inset panel. Estimates are weighted to adjust for differences in characteristics of individuals for whom anorectal specimens were collected or not collected during the study period. (**B**) Incidence rates of sexually-transmitted infections based on diagnosed cases (blue) and estimated rates of infection, corrected for testing effort (red). Rates are presented as infections per 100 person-years during the study period, within the weighted study cohort, for MPXV, *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Treponema pallidum*. Rates for *T. pallidum* are presented for individuals with no history of prior syphilis, due to use of serological diagnosis; rates for MPXV among individuals without prior syphilis diagnoses are presented below. (**C**) Estimates of the under-reporting multiplier, overall and for subgroups defined by demographic and clinical characteristics. We present alternative estimates based on an instantaneous prevalence comparison in **Table S3** along with results of sensitivity analyses (**D**) Ratios comparing the estimated under-reporting multiplier across the distinct subgroups for which we present data.



Fig #2. Testing-corrected incidence rates and vaccine effectiveness estimates. (**A**) Estimates of JYNNEOS vaccine effectiveness against diagnosed mpox, against MPXV infection, and against progression to diagnosed mpox, given MPXV infection. Effect estimates against diagnosed mpox are based on a case-control analysis comparing vaccination status among diagnosed mpox cases to individuals diagnosed with gonorrhea. Estimates of effectiveness against MPXV infection are pooled across analyses based on the incidence rate ratio of MPXV infection comparing vaccinated to unvaccinated individuals, and comparing prior vaccination among individuals testing positive or negative for MPXV infection by anorectal swabbing; estimates of effectiveness against disease progression are derived mathematically from estimated effectiveness against diagnosed mpox and against MPXV infection (**Table S7**). (**B**) Incidence rates of MPXV infection, corrected for testing effort, stratified by individuals' history of JYNNEOS vaccination. (**C**) Dates of receipt of first JYNNEOS doses among vaccinated cohort members. (**D**) Coverage of ≥1 or ≥2 JYNNEOS doses among cohort members as of May 1, 2024, plotted against an axis indicating individuals' age as of 1 May, 2022. Panels include all cohort members (left) as well as those with clinical notes indicating provider awareness of male sex partners (right).



Fig #3. Modeling the contribution of individuals with diagnosed mpox and undetected MPXV infection to transmission. (**A**) Maximum values of the dispersion parameter, *k*, obtained under scenarios where only individuals with detected infections transmit MPXV. Modeled scenarios minimize dispersion in the offspring distribution by assuming uniform numbers of secondary infections for the proportion $(1-\beta)$ of individuals with diagnosed mpox, and no secondary infections for the proportion β of individuals with undetected MPXV infection. The reproduction number *R* denotes the mean number of secondary infections caused by each infected individual. We consider scenarios with under-reporting multipliers of $\beta^{-1} = 33$ (per our primary analysis) and $\beta^{-1} = 17$ (as a sensitivity analysis). Shaded areas delineate 95% confidence intervals around our estimates, and dotted red lines correspond to $k = 0.3$, as estimated in previous studies (*26–28*). (**B**) Minimum proportion of transmission attributable to undetected infections, under scenarios with $k = 0.3$ and deterministic assignment of transmission links to index cases with diagnosed mpox. We present estimates with under-reporting multipliers of $\beta^{-1} = 33$ (per our primary analysis) and $\beta^{-1} = 17$, as a sensitivity analysis. (**C**) Offspring distribution characteristics under scenarios with differing transmission dynamics. Top and middle rows present cumulative distribution functions for the number of secondary infections (*U*) caused by individuals with undetected MPXV infection and diagnosed mpox, respectively, varying the rate ratio of transmission by individuals with diagnosed mpox relative to those with undetected MPXV infection, $\exp(\delta_1)$, from 2 to 20. Bottom row panels indicate the total proportion of transmission attributable to individuals with undetected infection for each value of δ_1. Panels are grouped into columns according to *R* values employed for each analysis (*R*=0.7, 1.0, 1.2, 1.5, 2.0, 3.5).



Fig. #4. Under-reporting estimates based on external surveillance studies and phylogenetic analyses. (**A**) Estimated under-reporting multipliers comparing MPXV infection prevalence observed in anorectal specimen testing to expected prevalence based only on diagnosed cases in each study setting. We detail the included studies and data providing the basis for estimates in **Table S4** and **Table S5**. Risk-adjusted estimates account for expected differences in MPXV detection in samples recruited in STI clinic settings as compared to the general MSM population (**Fig. S4**). The tan shaded area delineates the 95% confidence interval around our primary estimate within the KPSC study population (33; 95% confidence interval [CI]: 16-68) as a basis for comparison. (**B**) Estimated under-reporting multipliers comparing anti-MPXV IgG seroprevalence to expected seroprevalence based on cumulative diagnosed cases in the study setting. We present pooled estimates of under-reporting multipliers across studies, with and without risk adjustment, in **Table S6**. (**C**) Under-reporting multipliers based on a comparison of diagnosed cases to the estimated population size of MPXV infections in Los Angeles County from phylogenetic analyses of sequenced cases, for the period from May 21 to October 14, 2022. Estimates are conditioned on the reproduction number, *R*. We illustrate the probability density of mean daily *R* values throughout the analysis period in purple (top left inset panel). Pooled estimates presented in bold at the bottom of the figure are weighted according to the period-specific probability density of *R*. We present alternative estimates assuming lower or higher values of the dispersion parameter *k* in **Fig. S6**. (**D**) Estimated under-reporting multipliers comparing diagnosed cases to the estimated population size of MPXV infections in Los Angeles County, based on phylogenetic analyses, for the period from October 15, 2022 to December 31, 2024.

MATERIALS AND METHODS

1: Inferring under-reporting via prospective testing for subclinical infections. We estimated under-reporting multipliers by comparing prevalence of anorectal MPXV shedding in a cohort of MSM receiving care from KPSC to expected prevalence based on diagnosed cases alone within the same cohort. Below we describe enrollment criteria, testing, and estimation procedures underlying this analysis.

Sections that follow address further analyses of vaccine effectiveness, transmission dynamics, and validation studies for our under-reporting findings based on both meta-analyses of other studies and phylogenetic analyses.

1.1: Study cohort. Eligible individuals were males born between January 1, 1972 and May 1, 2008 who had been members of KPSC health plans continuously since at least 1 May, 2023 (allowing enrollment gaps <45 days), ensuring capture of prior-year healthcare utilization and recent STI history. Our age-based restrictions limited the population to individuals born after cessation of smallpox vaccination for the US general public, improving comparability of our estimates to those of other prospective testing studies (e.g., *5, 35*) and constraining the sample to age groups experiencing the greatest risk of mpox and other STIs (*9*). We further restricted eligibility to individuals who: received ≥1 test anorectal *N. gonorrhoeae*/*C. trachomatis* test after 1 May, 2023, as such testing is indicated only for MSM, and who over the same period had any appointment or received any laboratory test, prescription fill, immunization, or other care at the West Los Angeles Medical Center or Los Angeles Medical Center. As these were the KPSC facilities diagnosing the greatest number of mpox cases since 2022, individuals receiving care from these facilities were expected to have the greatest likelihood of mpox diagnosis in the event of clinical illness.

1.2: Testing. Screening for sexually-transmitted infections (STIs) is recommended every 3-6 months for MSM receiving HIV pre-exposure prophylaxis and those living with HIV who continue to have new sex partners, as well as for those receiving doxycycline post-exposure prophylaxis (*48, 49*). Between May 29 and November 13, 2024, we obtained a total of 1,190 remnant anorectal specimens submitted for *N. gonorrhoeae*/*C. trachomatis* screening among 1,054 of the 7,930 study cohort members during visits to the West Los Angeles or Los Angeles Medical Center facilities. Samples were maintained at –20ºC and tested at the Southern California Permanente Medical Group, Regional Reference Laboratories, Chino Hills, using a clinically-validated multiplex real-time PCR assay that detects MPXV (clades I/II) and non-variola Orthopoxvirus (NVAR), as previously described (*50, 51*). We list primer and probe sequences for both tests in **Table S9**.

1.3: Sample weighting. To address differences in characteristics of individuals from whom we received or did not receive a specimen for MPXV testing during the study period, we adjusted estimates of mpox incidence and MPXV infection prevalence within the KPSC study cohort via stabilized inverse propensity weighting (*52*). We computed stabilized inverse propensity-of-testing weights (ω_i) using a logistic regression model defining receipt of testing as the outcome; covariates included individuals' age, race/ethnicity, health insurance payment source, neighborhood deprivation index (a community-level proxy for individual socioeconomic status), prior-year healthcare utilization across outpatient settings and history of emergency department presentation or inpatient admission, prior-year STI testing, receipt of HIV pre-exposure prophylaxis, receipt of doxycycline post-exposure prophylaxis, receipt of JYNNEOS, prior diagnoses of HIV, syphilis, gonorrhea, chlamydia, mpox, or other STIs, and prior diagnosis of alcohol or drug abuse.

1.4: Time-to-event analysis for under-reporting. To generate expected infection prevalence estimates based on diagnosed mpox cases, we sampled dates of MPXV exposure (τ_E), shedding onset (τ_S), symptoms onset (τ_Y) and shedding cessation (τ_C) for cases based on their dates of testing (τ_L). We estimated daily infection prevalence within the study cohort ($\pi(t)$) by dividing the sum of individuals expected to shed MPXV in anorectal specimens by the total enrolled population, applying weights as defined above, via

$$\pi(t) = \frac{\sum_i \omega_i \mathbb{I}[\tau_{S,i} \leq t]\mathbb{I}[\tau_{C,i} > t]}{\sum_i \omega_i}.$$

We abstracted data on duration of several stages within the natural history of MPXV infection to parameterize distributions for sampling event times τ_S and τ_C from observations τ_L (**Fig. S2**). From a study of reported cases followed prospectively from the date of diagnostic testing with repeated sampling, we estimated time from symptoms onset to cessation of anorectal viral DNA detection detectable by PCR ($\tau_C - \tau_Y$; (*53*)). From a case series of US mpox patients (*1*), we estimated times from symptoms onset to testing ($\tau_L - \tau_Y$). Last, from a study that prospectively followed high-risk contacts of confirmed mpox cases (*13*), we estimated times from exposure to onset of anorectal viral DNA detection detectable by PCR ($\tau_S - \tau_E$), as well as times from exposure to symptoms onset ($\tau_Y - \tau_E$). We assumed Gamma-distributed times to event and used maximum likelihood estimation to fit distribution parameters to reported data; where authors presented information on distribution quantiles only, without accompanying individual-level data, we fit Gamma distribution parameters minimizing summed squared errors between expected and reported distribution quantiles.

Our primary analysis related daily weighted, observed prevalence of infection within the anorectal swabbing study to expected infections based on reported cases in a likelihood-based framework. We defined the probability of experiencing onset of anorectal shedding on day *k* as

$$\lambda_k = \beta \frac{\sum_i \omega_i \mathbb{I}\left[\tau_{S,i} \geq k\right] \mathbb{I}\left[\tau_{S,i} < (k+1)\right]}{\sum_i \omega_i},$$

where β represented a multiplier relating the true number of individuals experiencing onset of shedding on day *k* to the expected number of individuals experiencing onset of shedding on day *k* based on diagnosed cases alone. Conditioned on experiencing shedding onset on day *k*<*t*, we defined the probability an individual *j* would be observed to shed on day *t* as $\Pr\left[Z_j(t) = 1 | k\right] = \Pr[(\tau_C - \tau_S) > k]$. The probability of not shedding on day *t* was thus the probability of not initiating shedding by day *t*, or experiencing shedding onset and cessation before day *t*:

$$\Pr\left[Z_j(t) = 0\right] = \prod_{k \leq t} \left((1 - \lambda_k) + \lambda_k \Pr[(\tau_C - \tau_S) < (t - k)]\right),$$

$$\Pr\left[Z_j(t) = 1\right] = 1 - \Pr\left[Z_j(t) = 0\right].$$

The weighted likelihood all $Z_j(t)$ observations was thus

$$\prod_j \left(\prod_t Z_j(t) \Pr\left[Z_j(t) = 1\right] + \left(1 - Z_j(t)\right) \Pr\left[Z_j(t) = 0\right] \right)^{\omega_j}.$$

Extending this framework for analyses comparing under-reporting between participant strata distinguished by a binary characteristic $X \in \{0,1\}$, as presented in **Fig. 1**, we defined

$$\lambda_{k,j} = \exp\left(\beta_0 + (1 - x_j(1 - \beta_1)\right) \frac{\sum_i \omega_i \mathbb{I}\left[\tau_{S,i} \geq k\right] \mathbb{I}\left[\tau_{S,i} < (k+1)\right] \mathbb{I}\left[x_i = x_j\right]}{\sum_i \omega_i \, \mathbb{I}\left[x_i = x_j\right]}.$$

We estimated the under-reporting multiplier β (or β_0 and β_1, for stratified analyses) by maximum likelihood, obtaining the covariance via the inverse of the Hessian matrix.

1.5: Comparison of observed to expected infection prevalence. We conducted an alternative analysis comparing observed to expected prevalence throughout the study period. We sampled values of the mean expected prevalence throughout the study period, $\bar{\pi} = \sum_t \pi(t) / (\max(t) - \min(t))$, via draws of τ_S and τ_C for each case, and sampled values of the observed prevalence within the anorectal specimen study as $p \sim \mathrm{Beta}\left(\sum_j \sum_t \omega_j z_j(t), \sum_j \sum_t \omega_j \left(1 - z_j(t)\right)\right)$. We defined our alternative estimate for the under-reporting multiplier $\beta = p/\bar{\pi}$, and sampled from β via 100,000 independent draws from *p* and $\bar{\pi}$.

1.6: Incidence rate estimation. We estimated incidence rates of MPXV infection within the reweighted sample, adjusted for reporting, as $\beta \sum_i \omega_i y_i / \sum_i \omega_i \min\left(\tau_{Y,i}, \tau_{F,i}\right)$ where $\tau_{F,i}$ was the earliest of the date of death, disenrollment, or study termination for individual *i*.

To contextualize our estimates of the incidence rate of MPXV infection, we also estimated incidence rates for infection with *N. gonorrhoeae*, *C. trachomatis*, and *T. pallidum*. We defined *N. gonorrhoeae* and *C. trachomatis* infections as any positive molecular test result separated by ≥30 days from any prior positive test result or diagnosis; we defined *T. pallidum* infection based on positive results for *Treponema*-specific IgG or IgM. To correct for potential under-ascertainment of these other STIs, we fit Poisson regression models relating individuals' rates of infection during the study period to their screening frequency in the prior year. Models defined counts of unique diagnoses (separated by ≥30 days from a previous diagnosis) with each infection during the study period as the outcome variable and included log-transformed person-time at risk as an offset term. The primary exposure of interest was the prior-year frequency of testing (between May 1, 2023 and April 30, 2024). For *N. gonorrhoeae* and *C. trachomatis*, *we* defined receipt of ≥4 tests as the "best-case" referent category based on guidelines that MSM should be screened up to every 3 months for continuation of HIV PrEP and doxycycline post-exposure prophylaxis (*48, 49*); for *T. pallidum*, we defined receipt of ≥2 tests as the "best-case" referent category due to the lower rate of infection and lack of evidence for increased incidence of syphilis diagnoses with testing at shorter intervals in the study population. To ensure measured testing behavior reflected engagement with screening

rather than test-seeking for symptomatic illness or known exposures, models adjusted for individuals' receipt of any gonorrhea diagnosis or chlamydia diagnosis in the prior year, as well as age group, insurance source, receipt of HIV PrEP and doxycycline post-exposure prophylaxis, receipt of JYNNEOS, HIV infection and prior syphilis diagnosis. As *T. pallidum* infection is diagnosed by serology, we limited analyses for this infection to individuals with no prior history of syphilis diagnoses or positive test results.

Regression parameters α_1 and α_2 compared rates of STI diagnoses associated with prior-year receipt of 0-1 tests versus ≥4 tests and 2-3 tests versus ≥4 tests, respectively, and thus represented reporting ratios for STI compared to a scenario where individuals' testing frequency met CDC recommendations. We defined the correction factor relating true rates of infection to rates of diagnoses as

$$\epsilon = \frac{\sum_i \omega_i(\alpha_1^{-1}\mathbb{I}[a_i < 2] + \alpha_2^{-1}\mathbb{I}[2 \leq a_i < 4] + \Pr\ \mathbb{I}[a_i \geq 4])}{\sum_i \omega_i}$$

and multiplied incidence of rates of STI diagnoses by ϵ to obtain incidence rates of infection. The corresponding equation for corrected incidence rates of *T. pallidum* infection was

$$\epsilon = \frac{\sum_i \omega_i(\alpha_1^{-1}\mathbb{I}[a_i < 2] + \alpha_2^{-1}\mathbb{I}[a_i \geq 2])}{\sum_i \omega_i}.$$

2: Vaccine effectiveness estimation. We aimed to estimate three classes of vaccine direct effects comparing counterfactual risk of mpox-related clinical outcomes among individuals who received JYNNEOS versus those who did not receive JYNNEOS. Following Halloran et al. (*54*), we considered that vaccination could protect against diagnosed mpox by: reducing individuals' susceptibility to acquiring MPXV infection, given exposure, by a factor $\mathrm{VE}_S = (1-\theta_S) \times 100\%$; and by reducing individuals' risk of progression to diagnosed mpox, given MPXV infection, by a factor $\mathrm{VE}_P = (1-\theta_P) \times 100\%$. The reduction in risk of diagnosed mpox, given vaccination, was thus $\mathrm{VE}_D = (1-\theta_S\theta_P) \times 100\%$.

We used a case-control design to estimate VE_D, and confirmed results of this primary analysis using a negative control-adjusted prospective cohort framework. We also estimated VE_S using two analysis frameworks, based on both case-control and prospective-cohort designs. We used the results of these analyses to estimate VE_P, defining

$$\mathrm{VE}_P = (1-\theta_P) \times 100\% = \left(1 - \frac{\theta_S\theta_P}{\theta_S}\right) \times 100\% = \left(1 - \frac{100 - \mathrm{VE}_D}{100 - \mathrm{VE}_I}\right) \times 100\%.$$

Our analyses considered pre-exposure JYNNEOS vaccination only, as no post-exposure prophylaxis with JYNNEOS occurred among cohort members during the study period. All previously-administered JYNNEOS doses were considered pre-exposure doses with respect to follow-up for mpox during the study period.

2.1: Estimation of vaccine effectiveness against diagnosed mpox. Our primary analysis estimating VE_D used a case-control framework comparing adjusted odds of prior vaccination among cases diagnosed with laboratory-confirmed mpox to controls diagnosed with laboratory-confirmed gonorrhea during the study period. This strategy was anticipated to mitigate confounding based on the expectation that receipt of JYNNEOS could be associated with individuals' risk of STI exposure as well as their engagement with sexual health services and likelihood of being diagnosed, if infected (*55, 56*); whereas JYNNEOS would not be expected to alter individuals' risk of gonorrhea, gonorrhea cases were expected to resemble mpox cases in sexual risk characteristics and healthcare-seeking behavior. We defined the product $\theta_S\theta_P$ as the adjusted odds ratio of prior JYNNEOS vaccination (receipt of any doses, 1 dose, or ≥2 doses) among mpox cases relative to controls diagnosed with gonorrhea, and estimated this term via conditional logistic regression. We defined matching strata on individuals' HIV infection status and (among HIV-negative individuals) receipt or non-receipt HIV PrEP; receipt of doxycycline post-exposure prophylaxis; and history of any syphilis diagnosis. Models further controlled for individuals' age group, receipt of *N. gonorrhoeae*/*C. trachomatis* testing in the prior year, and commercial or non-commercial insurance source (expected to proxy socioeconomic status) via covariate adjustment.

We conducted a sensitivity analysis leveraging the prospective design of the study and estimating VE_D via a negative control-corrected incidence ratio, following a previously-described framework (*57*) recently validated in a randomized controlled trial setting (*58*). This analysis used a two-stage approach; we first estimated adjusted incidence rate ratios (IRRs) comparing incidence of mpox diagnoses and gonorrhea diagnoses among JYNNEOS recipients (any receipt, 1 dose receipt, or ≥2 dose receipt) versus non-recipients. Considering that any apparent association of JYNNEOS vaccination with gonorrhea incidence would signify bias due to differential sexual risk and healthcare-seeking behaviors

among vaccine recipients and non-recipients, we used the estimated IRR for gonorrhea to adjust the causal effect estimate for the IRR of mpox associated with JYNNEOS vaccination, such that

$$\mathrm{VE}_D = (1 - \theta_S \theta_P) \times 100\% = \left(1 - \mathrm{IRR}_{\mathrm{mpox}}/\mathrm{IRR}_{\mathrm{gonorrhea}}\right) \times 100\%.$$

We estimated each IRR via Poisson regression models, defining mpox or gonorrhea diagnoses as the outcome variables and including log person-time at risk as an offset, and adjusted for all risk factors included in the primary analysis models (HIV infection, receipt of HIV PrEP, receipt of doxycycline post-exposure prophylaxis, prior syphilis diagnosis, age group, prior-year gonorrhea testing, and commercial insurance source) as covariates.

2.2: Estimation of vaccine effectiveness against MPXV infection. Our first analysis estimating VE_S defined θ_S as the adjust odds ratio of prior JYNNEOS receipt (any doses, one dose, or two doses) or non-receipt comparing individuals within the anorectal specimen testing study who received positive MPXV results to those receiving negative results. We considered the outcome of positive results from asymptomatic rectal specimen based on the assumption that infections captured within the testing study represented the source population from which diagnosed mpox cases would be drawn; although none of the 6 individuals receiving positive results in our study ultimately progressed to diagnosed illness, such progression has been identified in other studies employing similar designs (**Table S9**). We fit θ_S using conditional logistic regression models defining positive or negative test results from each specimen as the outcome, defining matching strata for individuals' HIV infection status and (among HIV-negative individuals) receipt or non-receipt HIV PrEP, receipt of doxycycline post-exposure prophylaxis, and history of any syphilis diagnosis, consistent with our analyses estimating VE_D. We included data from all specimens, and used the sandwich estimator to adjust variance estimates for repeat sampling of individuals.

We also estimated VE_S via the adjusted IRR of MPXV infection comparing previously-vaccinated individuals to unvaccinated individuals. These analyses applied under-reporting multipliers (β parameters, as described above) specific to the vaccinated and unvaccinated populations in defining MPXV incidence rates for the comparator populations.

3: Examining the role of undetected infections in transmission. We undertook two analyses aiming to clarify the potential contribution of individuals with undetected MPXV infections to transmission. The first quantified the minimum degree of dispersion (maximum value of *k*) corresponding to a scenario where individuals with undetected infection make no contribution to transmission, and compared this value to previously-reported estimates of *k* for MPXV based on prior phylogenetic studies (*26–28*). The second analysis estimated the proportion of infections caused by individuals with undetected infection under scenarios with $k = 0.3$, consistent with these prior estimates (*26–28*).

3.1: Minimum dispersion under scenarios without transmission by individuals with undetected infection. We first explored implications of the hypothesis that individuals who receive mpox diagnoses account for all transmission by estimating values of a dispersion parameter *k* that would correspond to this scenario. We measured the dispersion parameter as

$$k = \frac{R + R^2}{\mathrm{var}(U)}.$$

where *R* specified the reproduction number, or mean number of secondary infections (*U*) resulting from each index infection (*23–25*). Greater values of *k* correspond to lower degrees of dispersion in the number of infections caused by each index case; *k* approaches 0 as variance in *U* approaches ∞, and *k* approaches ∞ as variance in *U* approaches 0. Maximum values of *k*, corresponding to the minimum degree of dispersion, arise under a scenario assuming uniform numbers of secondary infections caused by individuals with detected infections:

$$U = \begin{cases} R\beta & \text{with probability } 1/\beta \\ 0 & \text{with probabiltiy } 1 - 1/\beta. \end{cases}$$

We sampled 10,000 distributions of *U* under each for $R \in 0.5, 0.6, \ldots 3.5$, and repeated analyses under a scenario where only half of individuals at risk for transmitting infection received diagnoses (e.g., due to lack of clinical recognition of symptoms), where

$$U = \begin{cases} R\beta/2 & \text{with probability } 2/\beta \\ 0 & \text{with probabiltiy } 1 - 2/\beta. \end{cases}$$

Across the range of *R* values considered, our analyses yielded maximum *k* estimates that remained consistently below the range of previously estimates (*26–28*), suggesting that the hypothesis of transmission only by diagnosed mpox cases implies an implausible degree of variation in individuals' risk of transmitting MXPV.

3.2: Contribution of undetected infections to transmission with realistic dispersion. We next sought to estimate the proportion of transmission that could be attributed to individuals with undetected infections under scenarios with *k*=0.3, consistent with published estimates (26–28). Defining $U \sim \text{Negative Binomial}(R \in 0.7, 0.8, \ldots, 3.5, k = 0.3)$, we drew values *U* and considered differing schemes for linking secondary infections to diagnosed or undiagnosed index cases.

Our first approach maximized the number of secondary infections attributed to diagnosed index cases. Defining $D = N/\beta$ as the number of diagnosed cases among *N* infections, for a sorted vector U' (with $u'_1 \geq u'_2 \geq \cdots \geq u'_N$), the proportion of infections attributable to diagnosed cases was $\sum_{i=1}^{D} u'_i / \sum_i^N u_i$, and the proportion attributable to undetected infections was $1 - (\sum_{i=1}^{D} u'_i / \sum_i^N u_i)$.

To relax this deterministic sorting framework, we next considered scenarios where individuals' likelihood of transmission was associated with being a diagnosed case. Defining Y as a vector indicating receipt of a diagnosis or no receipt of a diagnosis for a simulated population of cases (with probability $1/\beta$ of receiving a diagnosis), we defined $\mathbb{E}[U] = \exp(\delta_0 + \delta_1 Y)$ for δ_1 values corresponding to 2-, 4-, 10-, and 20-fold greater numbers of secondary infections attributable to individuals diagnosed with mpox compared to undetected MPXV infections. We defined $\delta_0 = \ln[R/\exp(\delta_1/\beta)]$ and solved via gradient descent for values of θ satisfying the condition

$$u_i \sim \text{Negative Binomial}(\exp[\delta_0 + \delta_1 y_i], \theta)$$

$$\frac{R + R^2}{\text{var}(U)} = 0.3$$

for sampled Y vectors of length 10,000.

Drawing from the resulting joint distributions of *Y* and *U*, the proportion of transmission attributable to individuals with diagnosed mpox was $\sum_i y_i u_i / \sum_i u_i$, while the proportion attributable to individuals with undetected infections was $\sum_i (1 - y_i) u_i / \sum_i u_i$.

4: Validation of under-reporting via meta-analysis of data from other settings. We conducted a systematic literature review of prior studies employing prospective testing for MPXV infection in anorectal specimens or anti-MPXV antibodies via blood specimens. We compared observed prevalence within the study populations to expected prevalence in the corresponding geographic areas based on local mpox case notification data from each setting, using a framework resembling our primary analyses within the KPSC study cohort. Analyses included corrections for potential differences in MPXV infection risk among individuals recruited in testing studies versus the general MSM population.

4.1: Literature search. We searched PubMed for the terms (mpox OR monkeypox) AND (prevalen* OR inciden* OR surveill*) in full-length research articles published in English between 1 April, 2022 and 31 May, 2025, yielding 580 articles. We reviewed articles to identify those presenting results of studies that prospectively or retrospectively evaluated (*a*) prevalence of MPXV detection via anorectal samples among MSM who were not clinically suspected to be experiencing mpox disease, or (*b*) prevalence of anti-MPXV IgG detection among MSM who were not clinically suspected to be experiencing mpox disease, and who were not recruited based on clinical knowledge or suspicion of prior MPXV infection. We limited studies to those undertaken in regions where mpox was not understood to be endemic prior to 2022. Studies that did not exclude non-MSM from participation, or that did not present data stratified by MSM status, were eligible for inclusion if ≥70% of the sample were cisgender MSM or reported transgender/non-binary gender expression. Due to the rare nature of the outcome, we excluded studies that enrolled <100 individuals. To supplement our search, we conducted forward and backward citation tracking in Google Scholar from articles that met inclusion criteria to identify additional articles for screening.

To ensure comparability with our findings, we included results from anorectal specimens only when studies presented results from both anorectal and oropharyngeal specimen testing. We excluded studies that presented results from other specimen types (e.g., urine or saliva) without disaggregation of positive and negative results by specimen source. For serological studies that included vaccinated persons, we restricted eligibility to those using assays distinguishing naturally-acquired from MVA-induced antibody responses.

4.2: Comparison of observed-to-expected prevalence in other settings. Within each setting where infection prevalence or seroprevalence studies were undertaken, we obtained publicly-reported mpox case counts at the finest-available temporal and spatial resolution. We estimated expected prevalence of infection, based on observed cases alone, by sampling dates of exposure (τ_E), onset of MPXV shedding (τ_S), and cessation of shedding (τ_C), as described above for analyses within the KSPC study cohort; for settings where cases were aggregated by dates of reporting rather than dates of testing,

we assumed a 1-day lag from the date a diagnostic test was performed to the reporting date. Where location-specific data were available on the proportion of mpox cases occurring among MSM, we multiplied daily case counts by this proportion to account for cases among MSM only; where such data were not available, we assumed MSM accounted for 95% of cases (*1*). For settings aggregating case notifications by week, we modeled daily diagnoses over the corresponding weeks as 1/7th of the weekly total.

We estimated expected daily infection prevalence, accounting for reported cases alone, by dividing the total number of individuals expected to shed MPXV each day by estimates of the corresponding MSM population size. We obtained MSM population denominators for each geographic area via a literature search, using census data from each region to project changes in population size from historical estimates (**Table S5**). For serological studies, we assumed onset of detectable IgG at time of shedding cessation, based on previous evidence of times to seroresponse after natural infection (*59, 60*) and vaccination (*61*). We propagated uncertainty across 100,000 sampled time series of the daily prevalence of infection and seropositivity, and defined expected period-wide prevalence or seroprevalence as the mean of daily values over the enrollment period of each study, as described above for analyses comparing observed to expected prevalence within the KPSC study cohort.

4.3: Risk normalization for reporting multipliers in other settings. Consistent with the rationale for inverse propensity weighting in the KPSC study, we expected that comparisons of MPXV infection prevalence or seroprevalence within study populations to mpox incidence among MSM in the surrounding geographic area could be biased by differences in risk among MSM enrolled in clinic-based samples and general-population samples. We used a two-stage procedure to correct for such bias. Because prior studies have provided estimates of the association of mpox risk with MSM's number of anal sex partnerships over the preceding 21 days (*2, 62*), and because total numbers of anal sex partnerships over specified intervals are a frequently-collected and frequently-reported characteristic of participants in sexual health research, we sought to reconstruct distributions of (*a*) anal sex partnerships per 3-week interval among MSM in clinic-based and general-population samples, and (*b*) relative risks of mpox, based on these sampled anal sex partnership counts.

We identified four studies reporting on anal sex partnership counts among MSM recruited in sexual health facilities *(63–65*); we constrained our search for studies to those undertaken within the US or Western Europe, as all included studies of MPXV prevalence were undertaken in these settings. We considered the sample enrolled in the ARTnet study as a reference population (*66, 67*) between July 2017 and January 2019. The sample for this study was recruited online among MSM directly after participation in the American Men's Internet Study (*68*), an annual online behavioral survey recruiting MSM via email blasts and banner advertisements on websites or mobile phone applications targeting differing audiences (gay social networking, gay general interest, general social networking, and geospatial social networking). While the lack of a reference frame precludes comparison of the characteristics of the surveyed population to all MSM, consistency of STIs incidence within this study sample and US surveillance data suggest risk characteristics of the population are representative of those of MSM in general. Specifically, HIV prevalence within the study sample was 10.8%, comparable to the estimate of 11.1% prevalence of diagnosed HIV infection among all US MSM (*69*). Gonorrhea incidence within the sample was 5.07 cases/100 person-years, comparable to the estimate of 5.17 cases/100 person-years among MSM (*70*). Additionally, prior comparative studies have reported that sexual risk behaviors are similar in MSM samples recruited through such online surveys and those recruited via physical venue-based sampling (*71*).

To account for the right-tailed shape of the distribution of individuals' reported anal sex partnerships, we considered this count to follow a negative binomial distribution for the recall interval (τ days) used in each study, $Z_\tau \sim \text{Negative Binomial}(p, r)$. We parameterized negative binomial distributions using either reported means and variances of distributions or via least-squares fitting to reported distribution quantiles. We sampled from the fitted distributions for pseudo populations of 1 million individuals and projected total partnership counts for individuals over a 3-week interval by multiplying the resulting samples by the factor $21/\tau$. To accommodate non-integer valued results, we drew counts probabilistically based on the remainder, with $z_{21}(i) = \text{Floor}[z_{21}^*(i)] + \text{Bern}(z_{21}^*(i) - \text{Floor}[z_{21}^*(i)])$. We used the association of anal sex partnership counts over a 21-day period from a test-negative design case-control study of mpox as the primary basis for assigning risk based on partnership counts (*2*). Compared to individuals who reported 0-1 anal sex partners in the 21 days preceding symptoms, adjusted odds ratios associated with reporting 2-3 partners and ≥4 partners were 2.2 (1.0-4.8) and 3.8 (1.7-8.8). We used these estimates to define and sample from probability distributions for individuals' relative risk of mpox $\pi(i)$ given their sampled partnership history, $f(\pi(i)|z_{21}(i))$, considering the adjusted odds ratio and relative risk to be equivalent under the test-negative design framework (*72*). We repeated this analysis using alternative, model-based estimates of the relative risk of mpox given partnership history (*62*), which yielded similar risk multipliers for adjustment.

*4.4: Pooling of reporting under-reporting multipliers***.** We pooled estimates of the (log-transformed) under-reporting multiplier across all validation samples (molecular surveillance studies; serosurveillance studies) using inverse variance-weighted random effects models (*73*), for both unadjusted and risk-adjusted analyses.

5: Validation of under-reporting via phylogenetic analyses. Last, we sought to estimate under-reporting multipliers within Los Angeles County by comparing the number of diagnosed cases to an estimate of the total MPXV viral population size generated by phylogenetic analyses. As detailed below, our workflow comprised generating a maximum-likelihood phylogeny of MPXV, generating estimates of the sampling proportion (ρ) accounting for both local transmission and repeated introductions of MPXV into Los Angeles County, and deriving the under-reporting multiplier β from our estimates of *p*. Here, *p* is defined as the ratio of the number of sequenced mpox cases to the effective population size ($N_{\text{sequenced}}/N_{\text{eff}}$) of MPXV in Los Angeles County (*38, 74, 75*). We describe these steps below together with a simulation study validating the framework for estimating ρ.

5.1: Phylogenetic inference. We used all available MPXV clade IIb genomes found on Genbank on January 20, 2025 and identified local transmission clusters in Los Angeles County under a framework outlined in a previous study of MXPV phylodynamics (*27*). We created a temporally-resolved phylogeny using a modified version of the Nextstrain (*76*) mpox workflow (https://github.com/nextstrain/mpox), which aligns sequences against the MK783032 (collection date: Nov. 2017) reference using nextalign (*77*). Briefly, this workflow included inferring a maximum-likelihood phylogeny using IQ-TREE (*78*) with a general time-reversible nucleotide substitution model, estimating molecular clock branch lengths via TreeTime (*79*). The resulting phylogeny is available from https://nextstrain.org/groups/blab/mpox/allcladeIIseqs.

Our analyses included 497 de-duplicated MPXV sequences for Los Angeles County cases. Of this total, 271 were sampled between May 21, 2022 (the date of the first notified mpox case in California associated with the ongoing clade IIb outbreak) and October 14, 2022, and 226 were sampled between October 15, 2022 and December 31, 2024. The Los Angeles County Department of Public Health (LACDPH) sequences mpox cases diagnosed by healthcare providers in Los Angeles County, we assume that any genome sequenced by LACDPH was sampled locally. As the California Department of Health (CDPH) supports sequencing efforts only for local public health departments without internal sequencing capacity, we assumed additional MPXV sequences (*N*=222) sequenced by CDPH were sampled in locations within California outside of Los Angeles County. We clustered all Los Angeles County sequences based on inferred internal node location using a parsimony-based approach to reconstruct the locations of internal nodes (*27, 39*).

We inferred the time-varying effective reproduction number (R_t), ρ, and phylogenies from all local clusters jointly using a birth-death skyline model (*36*), assuming that local outbreak clusters represented independent stochastic realizations of a transmission process with the same parameters (*80*). We assumed R_t to be piecewise-constant in intervals of 7 days, with

$$\log\left(\frac{R_{t+7}}{R_t}\right) \sim \text{Normal}(0, \sigma^2).$$

We estimated σ via Markov chain Monte Carlo sampling (MCMC) using BEAST2 (*37*). We allowed an 8-day mean infectious period (T_g), reflecting our assumption that detectable shedding of MPXV genetic material outlasts individuals' period at risk of onward transmission (as described in (*53*) and accounted for in our estimates of expected infection prevalence in anorectal specimens (**Fig. S2**)). We employed a strict molecular clock with a fixed value of 6×10^{-5} (*26*) and a HKY+Γ nucleotide substitution model with a fixed $\kappa = 18.5$ (*81*).Of note, the birth-death skyline model conditions on survival (*36*), meaning that it computes the probability of observing a phylogenetic tree conditional on observing at least one lineage, and assumes the host population to be unstructured. Code for implementing this adapted version is available from https://github.com/nicfel/bdsky.

5.2: Validation of estimation framework. Birth-death skyline models assume unstructured populations, and hidden population structure may bias inference results. Further, they do not model skewed offspring distributions as is the case for mpox transmission. To test the validity of our approach to estimating ρ under realistic mpox transmission dynamics, we simulated phylogenetic trees under using a stochastic, individual-based Susceptible-Exposed-Infectious-Recovered (SEIR) model with superspreading (*82*). We modeled importation assuming a constant force of introduction per unit time, and (as described above) assumed an offspring distribution with $U \sim \text{Negative Binomial}(R, k)$. Primary analyses defined $k = 0.3$, consistent with previous estimates for MPXV (*26–28*); we additionally explored performance of the method with $k = 0.1$ (represent extreme dispersion) and $k = 1$ (representing low dispersion). To approximate real-life sampling dynamics, we parameterized time to sampling via the estimated time to healthcare presentation among UK mpox patients in 2022 (*83*). We also tested performance under lower sampling schemes reducing the sampling by 50% and 90%, relative to observed levels. We recorded structured phylogenetic trees from model output and simulated corresponding genetic sequences using Seq-Gen (*84*), assuming an HKY substitution model, a genome size of 197,000bps, and a clock rate of 6×10^{-5}. We then ran simulated outputs through our multi-tree birth-death modeling pipeline and compared the estimated sampling proportion to input parameter values.

Relating the sampling proportion to the number of infections. We used a previous derivation (*38*) of the relationship between N_{eff} and the total number of infections, N_{tot}, to generate reporting fractions based on our estimates of ρ from

each analysis period (May 21 through October 14, 2022 and October 15, 2022 through December 31, 2024). Defining a coalescence rate $\lambda = 1/\left(N_{\text{eff}} T_g\right)$ and an offspring distribution $U \sim \text{Negative Binomial}(R, k)$,

$$\lambda = \frac{R(1 + 1/k)}{N_{\text{tot}} T_g},$$

such that $N_{\text{tot}} = R(1 + 1/k) N_{\text{eff}}$. With $\rho = N_{\text{sequenced}}/N_{\text{eff}}$, we obtain numerical estimates of N_{tot} during each analysis period as

$$N_{\text{tot}} = \frac{R\left(1 + \frac{1}{k}\right) N_{\text{sequenced}}}{\rho}$$

and obtain conditional values of β_R by dividing total diagnosed cases by N_{tot}. We present estimates of β_R across a range of R estimates. Additionally, we obtain period-specific pooled estimates for β weighting these conditional values by $\Pr(R_t = R)$ for mean R_t values over each analysis period, i.e.

$$\beta_{\text{pooled}} = \sum_i \beta_{R_i} \Pr\left(R_t = R_i\right).$$

Table S1: Characteristics of the study cohort and individuals tested.

Characteristic		Frequency, *n* (%)			Reweighted frequency[1]		
		Full cohort	Individuals tested	Individuals not tested	Full cohort	Individuals tested	Individuals not tested
		N=7,930	*N*=1,054	*N*=6,876			
Age group							
	16-25	996 (12.6)	70 (6.6)	926 (13.5)	12.5%	11.9%	12.6%
	26-35	3,310 (41.7)	460 (43.6)	2,850 (41.4)	41.9%	43.0%	41.7%
	36-45	2,714 (34.2)	407 (38.6)	2,307 (33.6)	33.9%	31.9%	34.2%
	≥46	910 (11.5)	117 (11.1)	793 (11.5)	11.7%	13.2%	11.5%
Race/ethnicity							
	White, non-Hispanic	2,244 (28.3)	319 (30.3)	1,925 (28.0)	28.1%	27.1%	28.3%
	Black, non-Hispanic	738 (9.3)	92 (8.7)	646 (9.4)	9.4%	10.1%	9.3%
	Asian/Pacific Islander, non-Hispanic	797 (10.1)	109 (10.3)	688 (10.0)	10.4%	12.5%	10.1%
	Hispanic, any race	3,340 (42.1)	417 (39.6)	2,923 (42.5)	42.0%	41.1%	42.1%
	Other/unknown	811 (10.2)	117 (11.1)	694 (10.1)	10.1%	9.2%	10.2%
Health insurance source							
	Commercial plan	5,677 (71.6)	760 (72.1)	4,917 (71.5)	71.4%	70.3%	71.6%
	Pre-paid/self-payment plan	1,071 (13.5)	162 (15.4)	909 (13.2)	13.4%	12.5%	13.5%
	Medicaid plan	854 (10.8)	85 (8.1)	769 (11.2)	11.1%	12.9%	10.8%
	Other/unknown	328 (4.1)	47 (4.5)	281 (4.1)	4.2%	4.4%	4.1%
Neighborhood deprivation index[2]							
	Quartile 1 (least deprived)	2,525 (31.8)	373 (35.4)	2,152 (31.3)	31.9%	32.4%	31.9%
	Quartile 2	1,817 (22.9)	227 (21.5)	1,590 (23.1)	23.1%	24.3%	22.9%
	Quartile 3	1,647 (20.8)	184 (17.5)	1,463 (21.3)	20.9%	21.4%	20.8%
	Quartile 4 (most deprived)	1,934 (24.4)	270 (25.6)	1,664 (24.2)	24.0%	21.8%	24.3%
	Unknown	7 (0.1)	0 (0.0)	7 (0.1)	0.1%	0.0%	0.1%
Prior-year healthcare utilization							
	<5 outpatient visits	2,086 (26.3)	174 (16.5)	1,912 (27.8)	26.4%	27.3%	26.3%
	5-10 outpatient visits	3,603 (45.4)	571 (54.2)	3,032 (44.1)	45.3%	44.1%	45.4%
	11-20 outpatient visits	1,691 (21.3)	238 (22.6)	1,453 (21.1)	21.3%	21.2%	21.3%
	≥21 outpatient visits	550 (6.9)	71 (6.7)	479 (7.0)	7.0%	7.4%	6.9%
	Any emergency department visit	1,376 (17.4)	171 (16.2)	1,205 (17.5)	17.2%	16.4%	17.4%
	Any inpatient admission	235 (3.0)	26 (2.5)	209 (3.0)	2.9%	2.3%	3.0%
Prior-year gonorrhea testing							
	0-1 tests	2,132 (26.9)	97 (9.2)	2,035 (26.9)	27.0%	27.9%	26.9%
	2-5 tests	4,967 (62.6)	767 (72.8)	4200 (61.1)	62.6%	62.3%	62.6%
	≥6 tests	831 (10.5)	190 (18.0)	641 (9.3)	10.4%	9.8%	10.5%
Gender and sexual orientation							
	Known male partners	5,077 (64.0)	815 (77.3)	4,262 (62.0)	63.3%	58.8%	64.0%
	Transgender identity	268 (3.4)	6 (0.6)	262 (3.8)	3.7%	5.6%	3.4%
Sexual health measures							
	HIV pre-exposure prophylaxis	4,422 (55.8)	831 (78.8)	3,591 (52.2)	55.4%	53.1%	55.7%
	Doxycycline post-exposure prophylaxis	447 (5.6)	69 (6.5)	378 (5.5)	5.8%	6.8%	5.6%
	1 JYNNEOS dose	1,231 (15.5)	172 (16.3)	1,059 (15.4)	15.6%	16.2%	15.5%
	≥2 JYNNEOS doses	3,462 (43.7)	631 (59.9)	2,831 (41.2)	43.8%	45.0%	43.7%
History of sexually transmitted infections							
	HIV infection	1,435 (18.1)	165 (15.7)	1,270 (18.5)	18.6%	21.4%	18.1%
	Prior syphilis diagnosis	1,073 (13.5)	160 (15.2)	913 (13.3)	13.9%	16.0%	13.5%
	Prior-year gonorrhea: 1 diagnosis	965 (12.2)	202 (19.2)	763 (11.1)	12.5%	14.1%	12.2%
	Prior-year gonorrhea: ≥2 diagnoses	227 (2.9)	52 (4.9)	175 (2.5)	2.9%	2.8%	2.9%
	Prior-year chlamydia: 1 diagnosis	841 (10.6)	156 (14.8)	685 (10.0)	10.8%	12.0%	10.6%
	Prior-year chlamydia: ≥2 diagnoses	123 (1.6)	31 (2.9)	92 (1.3)	1.6%	1.8%	1.6%
	Other STI in prior year	21 (0.3)	1 (0.1)	20 (0.3)	0.2%	0.1%	0.3%
	Prior mpox diagnosis	9 (0.1)	2 (0.2)	7 (0.1)	0.1%	0.1%	0.1%
Other risk factors							

Alcohol or drug abuse diagnosis	821 (10.4)	93 (8.8)	728 (10.6)	10.3%	9.7%	10.4%

[1]We calculate stabilized weights via logistic regression with receipt of testing as the outcome variable to balance characteristics of individuals who did or did not receive testing as described in Section 1.3.
[2]Neighborhood deprivation index is computed at the census-tract level according to a previously-described framework (*85*).

Table S2: Characteristics of individuals testing positive for MPXV in testing study and those receiving mpox diagnoses.

Characteristic		Frequency, *n* (%)		
		MPXV negative (testing study)	MPXV positive (testing study)	Diagnosed mpox cases
		N=1,048	*N*=6	*N*=15
Age group				
	16-25	70 (6.7)	0 (0.0)	1 (6.7)
	26-35	457 (43.6)	3 (50.0)	8 (53.3)
	36-45	405 (38.6)	2 (33.3)	5 (33.3)
	≥46	116 (11.1)	1 (16.7)	1 (6.7)
Race/ethnicity				
	White, non-Hispanic	316 (30.2)	3 (50.0)	2 (13.3)
	Black, non-Hispanic	92 (8.8)	0 (0.0)	1 (6.7)
	Asian/Pacific Islander, non-Hispanic	108 (10.3)	1 (16.7)	1 (6.7)
	Hispanic, any race	415 (39.6)	2 (33.3)	10 (66.7)
	Other/unknown	117 (11.2)	0 (0.0)	1 (6.7)
Health insurance source				
	Commercial plan	756 (72.1)	4 (66.7)	13 (86.7)
	Pre-paid plan	162 (15.5)	0 (0.0)	1 (6.7)
	Medicaid plan	85 (8.1)	0 (0.0)	1 (6.7)
	Other/unknown	45 (4.3)	2 (33.3)	0 (0.0)
Neighborhood deprivation index[1]				
	Quartile 1 (least deprived)	373 (35.6)	0 (0.0)	3 (20.0)
	Quartile 2	225 (21.5)	2 (33.3)	5 (33.3)
	Quartile 3	183 (17.5)	1 (16.7)	1 (6.7)
	Quartile 4 (most deprived)	267 (25.5)	3 (50.0)	6 (40.0)
Prior-year healthcare utilization				
	<5 outpatient visits	173 (16.5)	1 (16.7)	2 (13.3)
	5-10 outpatient visits	569 (54.3)	2 (33.3)	11 (73.3)
	11-20 outpatient visits	235 (22.4)	3 (50.0)	2 (13.3)
	≥21 outpatient visits	71 (6.8)	0 (0.0)	0 (0.0)
	Any emergency department visit	169 (16.1)	2 (33.3)	4 (26.7)
	Any inpatient admission	26 (2.5)	0 (0.0)	1 (6.7)
Prior-year gonorrhea testing				
	0-1 tests	96 (9.2)	1 (16.7)	1 (6.7)
	2-5 tests	764 (72.9)	3 (50.0)	13 (86.7)
	≥6 tests	188 (17.9)	2 (33.3)	1 (6.7)
Gender and sexual orientation				
	Known male partners	809 (77.2)	6 (100.0)	11 (73.3)
	Transgender identity	6 (0.6)	0 (0.0)	1 (6.7)
Sexual health measures				
	HIV pre-exposure prophylaxis	827 (78.9)	4 (66.7)	10 (66.7)
	Doxycycline post-exposure prophylaxis	68 (6.5)	1 (6.7)	2 (13.3)
	1 JYNNEOS dose	170 (16.2)	2 (33.3)	3 (20.0)
	≥2 JYNNEOS doses	628 (59.9)	3 (50.0)	4 (26.7)
History of sexually transmitted infections				
	HIV infection	164 (15.6)	1 (16.7)	3 (20.0)
	Prior syphilis diagnosis	158 (15.1)	2 (33.3)	4 (26.7)
	Prior-year gonorrhea: 1 diagnosis	200 (19.1)	2 (33.3)	3 (20.0)
	Prior-year gonorrhea: ≥2 diagnoses	52 (5.0)	0 (0.0)	1 (6.7)
	Prior-year chlamydia: 1 diagnosis	156 (14.9)	0 (0.0)	5 (33.3)
	Prior-year chlamydia: ≥2 diagnoses	31 (3.0)	0 (0.0)	0 (0.0)
	Other STI in prior year	1 (0.1)	0 (0.0)	0 (0.0)
	Prior mpox diagnosis	2 (0.2)	0 (0.0)	0 (0.0)
Other risk factors				
	Alcohol or drug abuse diagnosis	93 (8.9)	0 (0.0)	2 (13.3)

[1]Neighborhood deprivation index is computed at the census-tract level according to a previously-described framework (*85*).

Table S3: Under-reporting estimates under alternative analysis frameworks.

Sample	Weighted estimates (95% confidence interval)[1]					
	MPXV infection prevalence (95% confidence interval), %		MPXV infection incidence per 100 person-years at risk		Under-reporting multiplier (95% confidence interval)	
	Clinically undetected and diagnosed cases	*Expected from diagnosed cases only*[2]	*Clinically undetected and diagnosed cases*	*Diagnosed cases only*	*Time-to-event analysis (primary)*	*Instantaneous prevalence comparison*[3]
All testing results included (*primary*)	0.91 (0.40, 1.63)	0.035%	22.2 (8.4, 48.0)	0.61	33.1 (16.2, 67.6)	26.3 (11.6, 46.5)
Excluding repeat positive results	0.86 (0.38, 1.57)	0.035%	21.1 (7.9, 46.3)	0.61	31.4 (15.2, 65.2)	25.1 (10.8, 45.4)
Excluding consecutive samples at <30-day intervals	0.88 (0.39, 1.59)	0.035%	21.5 (8.0, 46.9)	0.61	31.9 (15.4, 66.4)	25.3 (10.9, 45.5)

[1]We calculate stabilized weights via logistic regression with receipt of testing as the outcome variable to balance characteristics of individuals who did or did not receive testing (**Table S1**) as described in Section 1.3.
[2]We estimate expected prevalence, accounting for diagnosed cases alone, by projecting time series of the number of individuals shedding infection each day, based on sampled times of onset and cessation of shedding as described in Section 1.4.
[3]We compare observed to expected prevalence throughout the study period according to the ratio $\beta = p/\bar{\pi}$ as described in Section 1.5.

Table S4: Estimated effectiveness of JYNNEOS vaccination.

Measure	Framework	Description	Data for comparison groups	Estimate (95% confidence interval)
Vaccine effectiveness against diagnosed mpox, $\mathrm{VE}_D = (1 - \theta_S \theta_P) \times 100\%$	Case-control design[1]	Compares adjusted odds of prior vaccination among individuals with diagnosed mpox (cases) versus individuals with gonorrhea (controls) via conditional logistic regression. Matching strata included individuals' HIV infection status and (among HIV-negative individuals) receipt or non-receipt HIV PrEP; receipt of doxycycline pre-exposure prophylaxis; and history of any syphilis diagnosis. Models further controlled for individuals' age group, receipt of *N. gonorrhea*/*C. trachomatis* testing in the prior year, and commercial or non-commercial insurance source (expected to proxy socioeconomic status) via covariate adjustment.	Controls (*gonorrhea diagnosed*)	
			Any vaccination: 135 (31.6%)	– –
			1 dose: 83 (19.4%)	– –
			2 doses: 209 (48.9%)	– –
			Cases (*mpox diagnosed*)	
			Any vaccination: 8 (53.3%)	71.5% (9.1%, 91.1%)
			1 dose: 3 (20.0%)	54.7% (–89.2%, 89.1%)
			2 doses: 4 (26.7%)	78.3% (16.8%, 94.3%)
	Negative control-corrected cohort design[1]	Compares time to mpox diagnosis among JYNNEOS recipients to non-recipients, dividing the estimated adjusted hazard ratio by the adjusted estimated hazard ratio conveying the association of JYNNEOS vaccination with a negative-control outcome (gonorrhea), per Sanderson-Smith et al. (*57*). We estimated adjusted incidence rate ratios for each outcome via Poisson regression, controlling for HIV infection, receipt of HIV PrEP, receipt of doxycycline post-exposure prophylaxis, prior syphilis diagnosis, age group, prior-year gonorrhea testing, and commercial insurance source as covariates.	VE against mpox (*negative control-uncorrected*)	
			No vaccination: 0.8/100 PYAR	– –
			Any vaccination: 0.5/100 PYAR	59.6% (–17.9%, 86.1%)
			1 dose: 0.8/100 PYAR	29.1% (–176.5%, 81.7%)
			2 doses: 0.4/100 PYAR	69.6% (–6.1%, 91.4%)
			VE against gonorrhea (*negative control outcome*)	
			No vaccination: 20.8/100 PYAR	– –
			Any vaccination: 31.7/100 PYAR	–19.3% (–42.0%, –0.5%)
			1 dose: 30.1/100 PYAR	–16.9% (–47.3%, 7.2%)
			2 doses: 32.0/100 PYAR	–20.8% (–45.0%, –0.6%)
			VE against mpox (*negative control-corrected*)	
			Any vaccination	66.0% (–0.1%, 88.4%)
			1 dose	39.3% (–140.7%, 84.7%)
			2 doses	74.9% (10.8%, 92.9%)
Vaccine effectiveness against MPXV infection, $\mathrm{VE}_S = (1 - \theta_S) \times 100\%$	Matched test-negative design	Compares adjusted odds of prior vaccination among individuals testing positive for MPXV infection in anorectal specimens (cases) versus individuals testing negative (controls). Matching strata included individuals' HIV infection status and (among HIV-negative individuals) receipt or non-receipt HIV PrEP; receipt of doxycycline pre-exposure prophylaxis; and history of any syphilis diagnosis.	Controls (*testing negative*)	
			No vaccination: 274 (23.2%)	– –
			Any vaccination: 909 (76.8%)	– –
			1 dose: 184 (15.6%)	– –
			2 doses: 725 (61.3%)	– –
			Cases (*testing positive*)	
			No vaccination: 1 (14.3%)	– –
			Any vaccination: 6 (85.7%)	52.6% (–166.9%, 91.6%)
			1 dose: 2 (28.6%)	41.4% (–432.1%, 93.6%)
			2 doses: 4 (57.1%)	58.8% (–157.6%, 93.4%)
	Cohort design	Compares weighted incidence rates of MPXV infection among vaccinated individuals to unvaccinated individuals, corrected for estimated degree of under-reporting within each stratum.	No vaccination: 35.8/100 PYAR	– –
			Any vaccination: 11.7/100 PYAR	50.7% (–91.8%, 94.5%)
Vaccine effectiveness against progression to diagnosed mpox, given MPXV infection, $\mathrm{VE}_P = (1 - \theta_P) \times 100\%$	Model-based estimate	Obtained numerically, defining the risk (hazard, rate, …) ratio of diagnosed mpox associated with vaccination as the product of the risk (hazard, rate, …) ratio of infection, given vaccination, times the risk (hazard, rate, …) ratio of progression to disease, given infection, associated with vaccination.	– –	41.0% (–244.6%, 89.9%)

PYAR: Person-year at risk.
[1]We describe the estimation frameworks for protection against diagnosed mpox in Section 2.1.
[2]We describe the estimation frameworks for protection against MPXV infection in Section 2.2.

Table S5: Studies of MPXV infection prevalence or seroprevalence.

Study type	Location	Citation[1]	Population sampled	Dates	Observed prevalence[2]	Expected prevalence (95% confidence interval)
Molecular testing						
	Paris, France	Ferré et al., 2022 (*30*)	MSM living with HIV or taking HIV pre-exposure prophylaxis and receiving routine screening for *C. trachomatis* and *N. gonorrhoeae*, with no suspicion of mpox illness	June 5 to July 11, 2022	6.5% (13/200)	0.088% (0.036–0.163%)
	Antwerp, Belgium	De Baetselier et al., 2022 (*12*) and van Dijck, et al. (*31*)	MSM living with HIV or taking HIV pre-exposure prophylaxis and receiving routine screening for *C. trachomatis* and *N. gonorrhoeae*, with no suspicion of mpox illness			
				May 1-30, 2022	1.8% (4/224)	0.005% (0.002–0.009%)
				June 1-30, 2022	4.8% (7/146)	0.017% (0.009–0.025%)
				July 1 to 30 September, 2022	3.9% (7/181)	0.012% (0.001–0.028%)
	Geneva and Zürich, Switzerland	Hampel et al., 2023 (*32*)	MSM taking HIV pre-exposure prophylaxis and receiving routine screening for *C. trachomatis* and *N. gonorrhoeae*, with no suspicion of mpox illness	August 23 to October 4, 2022	1.0% (2/201)	0.006% (0.001–0.015%)
	Washington, DC, United States	Ogale et al., 2023 (*6*)	Individuals presenting for their first JYNNEOS vaccine dose, with no suspicion of mpox illness	August 11-31, 2022		0.031% (0.017–0.050%)
			With restriction to anorectal specimens		1.2% (2/164)	
			Without restriction to anorectal specimens		1.8% (3/164)	
	Barcelona, Spain	Agustí et al., 2024 (*14*)	MSM recruited at a community center with no suspicion of mpox illness	August 1 to October 31, 2022		0.024% (0.001–0.091%)
			With restriction to anorectal specimens		1.8% (2/112)	
			Without restriction to anorectal specimens		6.2% (7/113)	
Serological testing						
	San Francisco, United States	Minhaj et al., 2023 (*5*)	MSM receiving services at sexual health clinics with no suspicion of mpox illness	June 28 to August 26, 2022	8.0% (18/225)	1.02% (0.96–1.09%)
	New York, United States	Pathela et al., 2024 (*33*)	MSM receiving routine syphilis and HIV testing, with no history of receipt of vaccina virus-based vaccines and with no suspicion of prior mpox illness or exposure	July 7 to September 1, 2022	7.8% (16/166)	1.32% (1.09–1.63%)
	Rome, Italy	Matusali et al., 2023 (*34*)	Men presenting for their first JYNNEOS vaccine dose, with no history of receipt of vaccinia virus-based vaccines and with no prior mpox diagnosis	August 8 to September 9, 2022	12.8% (18/141)	0.19% (0.16–0.23%)
	Washington, DC, United States	Ogale et al., 2023 (*6*)	Individuals presenting for their first JYNNEOS vaccine dose, with no suspicion of mpox illness (limited to individuals providing anorectal swab)	August 11-31, 2022	14.5% (47/324)	1.17% (0.97–1.44%)
	Berlin, Germany	Marcus et al., 2024 (*35*)	MSM recruited in private practices and community-based checkpoints specialized in care for HIV and sexually-transmitted infections	April 1 to June 30, 2023	16.4% (149/908)	2.36% (1.95–2.90%)

[1]We identified studies through a systematic review including a PubMed search augmented by forward- and back-tracking of citations. We describe article eligibility criteria in Section 4.1.
[2]Analyses restricted results from molecular testing studies to those generated from anorectal specimens. We restricted results from serological testing studies to those enrolling unvaccinated or previously uninfected individuals (for studies during early phases of the outbreak in summer, 2022), or those using an antibody marker that distinguishes natural infection from vaccine response (for studies undertaken after vaccine implementation).

Table S6: Analytic basis for estimation of MSM population sizes for meta-analysis of surveillance studies.

Setting	Estimate (95% CI)	Description
Île-de-France (Paris region), France	95,661 (58,240–133,087)	A previous study (*86*) estimated the population of MSM within Île-de-France as of 2014 (*N*=93,178). We scaled this estimate by the population size of Île-de-France in 2014 and extrapolated to the population as of 2022.
Belgium	111,620 (92,413–130,811)	Two prior estimates (*87, 88*) of the population of MSM within Belgium were available (*N*=106,336 in 2013 and *N*=144,753 in 2015). We scaled these estimates by the population sizes of Belgium as of 2013 and 2015 and extrapolated to the population as of 2022. We multiplied by the population size of Belgium as of 2022 and assumed a normal distribution in pooling the estimates.
Lazio, Italy	128,865 (105,388–152,348)	Direct estimates of the population size of MSM in Lazio or Rome, Italy were not available. A previous study (*89*) estimated that MSM accounted for 2.7% of the adult male population in Verona, Italy as of 2014 (*N*=10,952); we scaled this estimate by the size of the population of men aged 16-64 years in Verona and multiplied by the size of the population of adult men aged 16-64 in the metropolitan city of Rome to obtain the urban MSM population. We added 1% of the population size of men aged 16-64 within the remaining administrative districts within Lazio to account for MSM outside the urban core, assuming a lower proportion in such regions would be MSM. We assumed the same ratio of the mean to standard deviation as reported in Verona and assumed a normal distribution.
Switzerland	88,758 (70,986–106,535)	A previous study (*90*) estimated the population of MSM within Switzerland as of 2011 (*N*=80,000). We scaled this estimate by the population size of Switzerland as of 2011, and multiplied by the population size of Switzerland as of 2022. We assumed a normal distribution.
Berlin, Germany	94,931 (76,312 - 113,496)	A previous study (*93*) estimated the population of MSM within Berlin as of 2008 (*N*=91,000). We scaled this estimate by the population size of Berlin in 2008 and extrapolated to the population as of 2024. Measures of uncertainty were not provided with the original report. We therefore defined standard deviation in the estimate as being equal to 10% of the mean and assumed a normal distribution.
Barcelona, Spain	42,613 (34,221 - 50,980)	A precious study (*94*) estimated the population of MSM comprised 5.3% of Barcelona's male population in 2012. Assuming this proportion remains constant through 2024, we extrapolated to the male population as of 2024. Measures of uncertainty were not provided with the original report. We therefore defined standard deviation in the estimate as being equal to 10% of the mean and assumed a normal distribution.
Washington, DC, United States	34,857 (28,840–42,895)	A previous study (*91*) estimated the population of MSM within Washington, DC as of 2016 (*N*=35,867). We scaled this estimate by the population size of Washington, DC in 2016 and extrapolated to the population as of 2022. Measures of uncertainty were not provided with the original report. We therefore defined standard deviation in the estimate as being equal to 10% of the mean and assumed a normal distribution.
San Francisco, California, United States	64,665 (60,607–68,730)	A previous study (*92*) estimated the population size of MSM within San Francisco as of 2017 (*N*=69,974). We scaled this estimate by the population size of San Francisco in 2017 and extrapolated to the population as of 2022. We assumed a normal distribution for reported uncertainty bounds and for our projection.
New York, New York, United States	218,375 (175,551–261,181)	A previous study (*91*) estimated the population size of MSM within New York City as of 2016 (*N*=224,020). We scaled this estimate by the population size of New York City in 2016 extrapolated to the population as of 2022. Measures of uncertainty were not provided with the original report. We therefore defined standard deviation in the estimate as being equal to 10% of the mean and assumed a normal distribution.

Table S7: Pooled estimates of under-reporting multipliers across other studies.

Studies included	Estimate (95% confidence interval)[1]	
	Without risk adjustment	With risk adjustment
All molecular testing studies	189 (90.7, 394)	136 (65.1, 283)
All serological testing studies	12.9 (5.59, 29.7)	9.24 (4.01, 21.3)
All molecular and serological testing studies	54.5 (20.7, 143)	39.1 (14.9, 103)

[1]Pooled estimates are generated via inverse variance-weighted random effects models including under-reporting multipliers from each selection of studies as described in Section 4.4.

Table S8: Symptoms among individuals testing positive for MPXV in molecular surveillance studies.

Reference	Citation	Setting and design	Outcomes[1]	
			Individuals followed	Individuals with symptoms or mpox diagnosis
Agustí et al., *Nat Comm* 2024	(*14*)	Testing via self-collected oropharyngeal and anorectal specimens with telephone follow-up 21 days after any positive test for symptom interview	7	2
de Batselier et al., *Nat Med* 2022; van Dijck et al., *Lancet Microbe* 2023	(*12, 31*)	Testing via oropharyngeal and anorectal specimens with accompanying symptom interview and clinical assessment, with follow-up 21-37 days after testing	18	5
Hampel et al., *Lancet Microbe* 2023	(*32*)	Testing via oropharyngeal and anorectal specimens within an existing longitudinal cohort study collecting symptoms data via web application	2	1
Ferré et al., *Ann Intern Med* 2022	(*30*)	Testing via anorectal specimens with subsequent outreach to individuals testing positive to collect symptoms data	13	2
Ogale et al., *Clin Infect Dis* 2024	(*6*)	Testing via anorectal and pharyngeal specimens within a cohort study involving 3 clinic visits over two months with symptoms interview at study visits.	3	1
Kaiser Permanente Southern California cohort (current study)	– –	Testing of anorectal specimens collected for STI screening, with monitoring for mpox-related healthcare utilization among cohort members in integrated healthcare system	6	0
Total			49	11

[1]Data encompass all individuals reported to experience infection, as detected by either oropharyngeal or anorectal specimens (a broader population than those included in analyses as reported in **Table S5**). Studies differed in monitoring for symptoms based on active or passive surveillance modalities.

Table S9: Real-time PCR assay sequences and thermal cycling conditions.

Assay	Primer/probe	Sequence
Non-variola *Orthopoxvirus*		
	Forward	5'-TCA ACT GAA AAG GCC ATC TAT mGA-3'
	Reverse	5'-GAG TAT AGA GCA CTA TTT CTA AAT CCmC A-3'
	Probe	5' - /5YakYel/CCA TGC AAT/ZEN ATA CGT ACA AGA TAG TAG CCA AC / 3IABkFQ/-3'
Mpox		
	Forward	5'-ACG TGT TAA ACA ATG GGT GAmU G-3'
	Reverse	5'-AAC ATT TCC ATG AAT CGT AGT mCC-3'
	Probe	5'-/56-FAM/TGA ATG AAT /ZEN/ GCG ATA CTG TAT GTG TGG G/3IABkFG/-3'



Figure S1. Characteristics of the KPSC study cohort. We present distributions of demographic and clinical characteristics within the (left) unweighted and (right) reweighted study cohort, with weights estimated by logistic regression to balance characteristics of individuals who received or did not receive MPXV testing by anorectal swabs. We present underlying data in **Table S1** and compare individuals testing positive or negative for MPXV, in the unweighted and weighted samples, in **Table S2**.



Figure S2. Modeled natural history of MPXV shedding in relation to date of reporting. We present (**A**) daily probabilities of MPXV detection in cutaneous and anorectal swabs, along with (**B**-**E**) fitted distributions for times-to-event for underlying epidemiologic parameters including times from exposure, onset of MPXV shedding, onset of clinical rash, and time to cessation of shedding detectable by PCR.



Figure S3. Expected and observed MPXV infection prevalence or seroprevalence in other settings. We illustrate estimated seroprevalence (left column; pink line, with shaded area delineating 95% confidence intervals) and infection prevalence (right column; blue line, with shaded area delineating 95% confidence interval) based on reported cases within each setting (**Table S5**; **Table S6**). Tan shaded areas delineate the study periods, with red lines denoting observations within each study (shaded areas delineate 95% confidence intervals around studies' prevalence or seroprevalence estimates).



Figure S4. Risk adjustment for comparison of individuals recruited in STI clinic settings to the general MSM population. We present comparisons of partnership counts within a 21-day recall period among differing MSM strata within a general population sample (**A**, **B**), as reported in the ARTnet study (*66, 67*), along with the strongly right-tailed distribution of partnership counts within the same recall period among individuals recruited in sexual health facilities (**C**) based on three studies (*63–65*). In the right-hand column, we illustrate reported associations of number of unprotected anal intercourse partnerships within a 21-day recall period with mpox risk based on a case-control study (*2*) and modeling study (*62*) (**D**). Below, we illustrate estimates of the relative risk of mpox among individuals recruited in sexual health facilities versus the general MSM population, for the individual studies presented in (**C**) and pooled across these studies, using relative risk parameters based on the case-control study (**E**) and the modeling study (**F**).



Figure S5. Sensitivity of birth-death skyline model to sampling and transmission heterogeneity. We illustrate the ability of our birth-death skyline model to accurately capture the true sampling proportions by simulating MPXV transmission dynamics with different values of the dispersion parameter (*k*=0.1, 0.3, 1.0) and sampling schemes. Under the sampling scheme "hosp", time to sampling is defined as the estimated time to present to healthcare in the UK in 2022 (83); the "half" and "tenth" sampling schemes reduce this rate by 50% and 90%, respectively. Histogram bars indicate the distribution of sampling proportion estimates from analyses of simulated data, while red dashed lines represent the true sampling proportion used to parameterize simulations. The center row of panels corresponds to $k = 0.3$, consistent with prior empirical findings (*26–28*), and demonstrates the best alignment between true and estimated values of *p* under each sampling scheme.



Fig. S6. Under-reporting estimates applying alternative estimates of dispersion. We illustrate under-reporting multipliers based on a comparison of diagnosed cases to the estimated population size of MPXV infections in Los Angeles County from phylogenetic analyses of sequenced cases, accounting for introductions from external geographies, for the periods from May 21 to October 14, 2022 and from October 15 to December 24, 2022. Within each panel, estimates are conditioned on the reproduction number, *R*. We illustrate the probability density of mean daily *R* values throughout the analysis period in purple. Pooled estimates presented in bold at the bottom of the figure are weighted according to the period-specific probability density of *R*. Top panels (**A**, **B**) present estimates under a scenario with extreme dispersion in the offspring distribution ($k = 0.1$), while bottom panels (**C**, **D**) consider a scenario with lower dispersion ($k = 0.5$).

SUPPLEMENTAL REFERENCES

48. US Centers for Disease Control & Prevention. Sexually transmitted infections treatment guidelines, 2021: screening recommendations (2024). https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm.

49. US Centers for Disease Control & Prevention. Sexually transmitted infections: Doxy PEP for bacterial STI prevention (2024). https://www.cdc.gov/sti/hcp/doxy-pep/index.html.

50. Nörz D, Tang HT, Emmerich P, Giersch K, Fischer N, Schmiedel S, et al. Rapid adaptation of established high-throughput molecular testing infrastructure for monkeypox virus detection. *Emerg Infect Dis* **28**, 1765–9 (2022).

51. US Centers for Disease Control & Prevention. Test procedure: non-variola Orthopoxvirus generic real-time PCR test (2022). https://www.cdc.gov/mpox/media/pdfs/2024/08/Non-variola-Orthopoxvirus-Generic-Real-Time-PCR-Test.pdf.

52. Robins JM, Hernán MÁ, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology* **11**, 550 (2000).

53. Suñer C, Ubals M, Tarín-Vicente EJ, Mendoza A, Alemany A, Hernández-Rodríguez Á, et al. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain. *Lancet Infect Dis* **23**, 445–53 (2023).

54. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. *Am J Epidemiol* **146**, 789 (1997).

55. Lewnard JA, Patel MM, Jewell NP, Verani JR, Kobayashi M, Tenforde MW, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. *Epidemiology* **32**, 508–17 (2021).

56. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies—II: types of controls. *Am J Epidemiol* **135**, 1029–41 (1992).

57. Sanderson E, Macdonald-Wallis C, Davey Smith G. Negative control exposure studies in the presence of measurement error: implications for attempted effect estimate calibration. *Int J Epidemiol* **47**, 587–96 (2018).

58. Feng S, Zhang Y, Khanam F, Voysey M, Pitzer VE, Qadri F, et al. The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial. *Lancet Global Health* **13**, e1122–31 (2025).

59. Sammartino JC, Cassaniti I, Ferrari A, Piralla A, Bergami F, Arena FA, et al. Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects. *J Med Virol* **95**, e28778 (2023).

60. Karem KL, Reynolds M, Braden Z, Lou G, Bernard N, Patton J, et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. *Clin Vaccin Immunol* **12**, 867–72 (2005).

61. Phipps K, Yates J, Pettit J, Bialosuknia S, Hunt D, DuPuis AP, et al. Short-lived neutralizing antibody responses to monkeypox virus in smallpox vaccine-naive persons after JYNNEOS vaccination. *Emerg Infect Dis* **31**, 237–45 (2025).

62. Spicknall IH. Modeling the Impact of Sexual Networks in the Transmission of Monkeypox virus Among Gay, Bisexual, and Other Men Who Have Sex With Men — United States, 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2024 Jun 26];71. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e2.htm

63. Montaño MA, Dombrowski JC, Dasgupta S, Golden MR, Manhart LE, Barbee LA, et al. Differences in sexually transmitted infection risk comparing preexposure prophylaxis users and propensity score matched historical controls in a clinic setting. *AIDS* **33**, 1773–80 (2019).

64. Montaño MA, Dombrowski JC, Dasgupta S, Golden MR, Duerr A, Manhart LE, et al. Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting. *AIDS Behav* **23**, 548–55 (2019).

65. DeVost MA, Beymer MR, Weiss RE, Shover CL, Bolan RK. App-based sexual partner seeking and sexually transmitted infection outcomes: a cross-sectional study of HIV-negative men who have sex with men attending a sexually transmitted infection clinic in Los Angeles, California. *Sex Transm Dis* **45**, 394–9 (2018).

66. Mann LM, Le Guillou A, Goodreau SM, Marcus JL, Sanchez T, Weiss KM, et al. Correlations between community-level HIV preexposure prophylaxis coverage and individual-level sexual behaviors among United States MSM. *AIDS* **36**, 2015–23 (2022).

67. Weiss KM, Goodreau SM, Morris M, Prasad P, Ramaraju R, Sanchez T, et al. Egocentric sexual networks of men who have sex with men in the United States: results from the ARTnet study. *Epidemics* **30**, 100386 (2020).

68. Zlotorzynska M, Sullivan P, Sanchez T. The Annual American Men's Internet Survey of behaviors of men who have sex with men in the United States: 2016 key indicators report. *JMIR Public Health and Surveill* **5**, e11313 (2019).

69. Rosenberg ES, Grey JA, Sanchez TH, Sullivan PS. Rates of prevalent HIV infection, prevalent diagnoses, and new diagnoses among men who have sex with men in US states, Metropolitan Statistical Areas, and counties, 2012-2013. *JMIR Public Health Surveill* **2**, e5684 (2016).

70. US Centers for Disease Control & Prevention. Sexually transmitted disease surveillance 2019 (2021). https://www.cdc.gov/sti-statistics/media/pdfs/2024/07/std-surveillance-2019.pdf.

71. Raymond HF, Rebchook G, Curotto A, Vaudrey J, Amsden M, Levine D, et al. Comparing internet-based and venue-based methods to sample MSM in the San Francisco Bay Area. *AIDS Behav* **14**, 218–24 (2010).

72. Lewnard JA. Uses of pathogen detection data to estimate vaccine direct effects in case–control studies. *J Royal Soc Interface* **17**, 20200161 (2020).

73. Viechtbauer W. Conducting meta-analyses in R with the metafor Package. *J Stat Softw* **36**, 1-48 (2010).

74. Kingman JFC. On the genealogy of large populations. *J Applied Probability* **19**, 27–43 (1982).

75. Koelle K, Rasmussen DA. Rates of coalescence for common epidemiological models at equilibrium. *J Royal Soc Interface* **9**, 997–1007 (2011).

76. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* **34**, 4121–3 (2018).

77. Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation calling and quality control for viral genomes. *J Open Source Softw* **6**, 3773 (2021).

78. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol Biol Evol* **37**, 1530–4 (2020).

79. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evol*. **4**, vex042 (2018).

80. Müller NF, Wüthrich D, Goldman N, Sailer N, Saalfrank C, Brunner M, et al. Characterising the epidemic spread of influenza A/H3N2 within a city through phylogenetics. *PLoS Pathog* **16**, e1008984 (2020).

81. Gonzalez G, Carr M, Kelleher TM, O'Byrne E, Banka W, Keogan B, et al. Multiple introductions of monkeypox virus to Ireland during the international mpox outbreak, May 2022 to October 2023. *Eurosurveillance*. 2024 Apr 18;29(16):2300505.

82. Müller NF, Wagner C, Frazar CD, Roychoudhury P, Lee J, Moncla LH, et al. Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State. *Sci Transl Med* **13**, eabf0202 (2021).

83. Hinch R, Panovska-Griffiths J, Ward T, Charlett A, Watkins N, Fraser C. Quantification of the time-varying epidemic growth rate and of the delays between symptom onset and presenting to healthcare for the mpox epidemic in the UK in 2022. *Sci Rep* **14**, 19755 (2024).

84. Rambaut A, Grass NC. Seq-Gen: an application for the Monte Carlo simulation of DNA sequence evolution along phylogenetic trees. *Bioinformatics* **13**, 235–8 (1997).

85. Messer LC, Laraia BA, Kaufman JS, Eyster J, Holzman C, Culhane J, et al. The development of a standardized neighborhood deprivation index. J Urban Health **83**, 1041–62 (2006).

86. Marty L, Cazein F, Panjo H, Pillonel J, Costagliola D, Supervie V. Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. *J Int AIDS Soc* **21**, e21500 (2018).

87. Marcus U, Hickson F, Weatherburn P, Schmidt AJ. Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses among MSM in 2009. *BMC Public Health* **13**, 919 (2013).

88. Marty L, Van Beckhoven D, Ost C, Deblonde J, Costagliola D, Sasse A, et al. Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. *J Int AIDS Soc* **22**, e25371 (2019).

89. Johnston LG, McLaughlin KR, Gios L, Cordioli M, Staneková DV, Blondeel K, et al. Populations size estimations using SS-PSE among MSM in four European cities: how many MSM are living with HIV? *Eur J Public Health* **31**, 1129–36 (2021).

90. Schmidt AJ, Altpeter E. The denominator problem: estimating the size of local populations of men-who-have-sex-with-men and rates of HIV and other STIs in Switzerland. *Sex Transm Infect* **95**, 285–91 (2019).

91. Grey JA, Bernstein KT, Sullivan PS, Purcell DW, Chesson HW, Gift TL, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* **2**, 314 (2016).

92. Raymond HF, McFarland W, Wesson P. Estimated population size of men who have sex with men, San Francisco, 2017. *AIDS Behav* **23**, 1576–9 (2019).

93. Marcus U, Schmidt AJ, Hamouda O, Bochow M. Estimating the regional distribution of men who have sex with men (MSM) based on Internet surveys. *BMC Public Health* **9**, 180 (2009).

94. Martí-Pastor M, de Olalla PG, Barberá M-J, Manzardo C, Ocaña I, Knobel H, et al. Epidemiology of infections by HIV, syphilis, gonorrhea, and *Lymphogranuloma venereum* in Barcelona City: a population-based incidence study. *BMC Public Health* **15**, 1015 (2015).